<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JOP</journal-id>
<journal-id journal-id-type="hwp">spjop</journal-id>
<journal-id journal-id-type="nlm-ta">J Psychopharmacol</journal-id>
<journal-title>Journal of Psychopharmacology</journal-title>
<issn pub-type="ppub">0269-8811</issn>
<issn pub-type="epub">1461-7285</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0269881110372818</article-id>
<article-id pub-id-type="publisher-id">10.1177_0269881110372818</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Paper</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Elucidation of neurobiology of anxiety disorders in children through pharmacological challenge tests and cortisol measurements: a systematic review</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Garcia de Miguel</surname><given-names>Berta</given-names></name>
<xref ref-type="aff" rid="aff1-0269881110372818">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Nutt</surname><given-names>David J</given-names></name>
<xref ref-type="aff" rid="aff2-0269881110372818">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hood</surname><given-names>Sean D</given-names></name>
<xref ref-type="aff" rid="aff3-0269881110372818">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Davies</surname><given-names>Simon JC</given-names></name>
<xref ref-type="aff" rid="aff4-0269881110372818">4</xref>
</contrib>
</contrib-group>
<aff id="aff1-0269881110372818"><label>1</label>University of Bristol, Psychopharmacology Unit, Bristol, UK</aff>
<aff id="aff2-0269881110372818"><label>2</label>Neuropsychopharmacology Unit, Division of Experimental Medicine, Imperial College London, London, UK</aff>
<aff id="aff3-0269881110372818"><label>3</label>School of Psychiatry and Clinical Neurosciences (M521), The University of Western Australia, Perth, Australia</aff>
<aff id="aff4-0269881110372818"><label>4</label>University of Bristol, Academic Unit of Psychiatry, Bristol, UK</aff>
<author-notes>
<corresp id="corresp1-0269881110372818">Simon JC Davies, University of Bristol, Academic Unit of Psychiatry, Bristol BS1 3NY, UK Email: <email>simon.davies@bristol.ac.uk</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2012</year>
</pub-date>
<volume>26</volume>
<issue>4</issue>
<fpage>431</fpage>
<lpage>442</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">British Association for Psychopharmacology</copyright-holder>
</permissions>
<abstract>
<p>Anxiety disorders are common both in adults and children. While there have been major advances in understanding the neurobiology of anxiety disorders in adults, progress has been more limited in the elucidation of the mechanisms underlying these disorders in childhood. There is a need to delineate childhood biological models, since anxiety represents a significant clinical problem in children and is a risk factor for the subsequent development of anxiety and depression in adulthood. We conducted a review of the literature regarding pharmacological challenge tests and direct hypothalamic–pituitary–adrenal axis measurement in children with anxiety disorders, with emphasis on panic disorder and social anxiety disorder. Studies identified were contrasted with those in adult panic disorder and social anxiety disorder. Despite this broad approach few studies emerged in children, with only 22 studies meeting inclusion criteria. When contrasted with adult neurobiological models of panic disorder and social anxiety disorder, children studied showed some abnormalities which mirrored those reported in adults, such as altered baseline respiration, altered responses to CO<sub>2</sub> challenge tests and blunted growth hormone response to yohimbine. However, results differed from adults with panic disorder and social anxiety in some aspects of noradrenergic and serotonergic function. For endpoints studied in panic disorder children, unlike adults, displayed a lack of baseline end-tidal CO<sub>2</sub> abnormalities and a different hypothalamic–pituitary–adrenal pattern response under low-dose CO<sub>2</sub>. The biology of these anxiety disorders in children may only partially mirror that of adult anxiety disorders. However, caution is required as the evidence is limited, and many studies combined patients with panic disorder and social anxiety disorder with other disorders or non-specific anxiety. Further research is required to fully understand the biology and progression of childhood anxiety disorders.</p>
</abstract>
<kwd-group>
<kwd>Anxiety</kwd>
<kwd>children</kwd>
<kwd>neurobiology</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0269881110372818" sec-type="intro">
<title>Introduction</title>
<p>The importance of anxiety disorders has been widely recognized. Epidemiological studies of adult populations state high prevalence rates of anxiety disorders both in the USA (<xref ref-type="bibr" rid="bibr69-0269881110372818">Kessler et al., 1994</xref>, <xref ref-type="bibr" rid="bibr67-0269881110372818">2005b</xref>) and in Europe (<xref ref-type="bibr" rid="bibr75-0269881110372818">Lépine, 2002</xref>; <xref ref-type="bibr" rid="bibr133-0269881110372818">Wittchen and Jacobi, 2005</xref>). Aside from simple phobia, social anxiety disorder (SAnD) is reported to be the most common anxiety disorder and the third most common psychiatric disorder (<xref ref-type="bibr" rid="bibr69-0269881110372818">Kessler et al., 1994</xref>). Studies using instruments consistent with DSM-III-R and DSM-IV criteria suggested lifetime prevalence rates for SAnD ranging between 4.1 (<xref ref-type="bibr" rid="bibr76-0269881110372818">Lépine and Lellouch, 1995</xref>) and 12% (<xref ref-type="bibr" rid="bibr66-0269881110372818">Kessler et al., 2005a</xref>). Panic disorder prevalence rates vary between studies but are most commonly reported around 4% (<xref ref-type="bibr" rid="bibr68-0269881110372818">Kessler et al., 2006</xref>). Both panic disorder and SAnD have high individual, economic and social costs (<xref ref-type="bibr" rid="bibr74-0269881110372818">Lépine, 2001</xref>), for example through suicide. They both follow a chronic course (<xref ref-type="bibr" rid="bibr35-0269881110372818">Fehm et al., 2005</xref>). Co-morbid disorders are frequent, especially major depression (<xref ref-type="bibr" rid="bibr45-0269881110372818">Gorman, 1996</xref>).</p>
<p>Anxiety disorders are also prevalent in children (<xref ref-type="bibr" rid="bibr40-0269881110372818">Ford et al., 2003</xref>), often having a relatively early age of onset (<xref ref-type="bibr" rid="bibr26-0269881110372818">Cartwright-Hatton et al., 2006</xref>; <xref ref-type="bibr" rid="bibr66-0269881110372818">Kessler et al., 2005a</xref>). SAnD prevalence rates in children and adolescents range from 0.5–4.0%, with high co-morbidity rates (<xref ref-type="bibr" rid="bibr28-0269881110372818">Chavira and Stein, 2000</xref>). Prevalence rates of panic disorder in community samples of children range between 0.5% and 5%, while rates in paediatric psychiatric clinics have been reported from 0.2–10%, this reported variation probably being attributable to the use of different diagnostic criteria (<xref ref-type="bibr" rid="bibr33-0269881110372818">Essau et al., 1999</xref>; <xref ref-type="bibr" rid="bibr77-0269881110372818">Lewinsohn et al., 1993</xref>; <xref ref-type="bibr" rid="bibr102-0269881110372818">Reed and Wittchen, 1998</xref>). Anxiety disorders with onset in adolescence or young adulthood predicts both subsequent onset of depressive disorders and severity of depressive illness (<xref ref-type="bibr" rid="bibr114-0269881110372818">Stein et al., 2001</xref>). One-quarter to one-half of adult cases of psychopathology may be preventable through effective treatment of juvenile diagnoses (<xref ref-type="bibr" rid="bibr70-0269881110372818">Kim-Cohen et al., 2003</xref>). It appears that the successful prevention and/or treatment of childhood anxiety disorders could markedly reduce not only the prevalence of adult anxiety disorders but also that of secondary depressive disorders (<xref ref-type="bibr" rid="bibr37-0269881110372818">Flannery-Schroeder, 2006</xref>). However, the existing scientific literature is marked by a far greater emphasis on these anxiety disorders in adults than in children.</p>
<p>Contemporary classification systems recognize several different anxiety disorders. Attempts have been made to sub-divide the anxiety disorder diagnoses according to their factor structure in large populations. Several studies (<xref ref-type="bibr" rid="bibr4-0269881110372818">Andrews et al., 2008</xref>; <xref ref-type="bibr" rid="bibr72-0269881110372818">Krueger, 1999</xref>; <xref ref-type="bibr" rid="bibr111-0269881110372818">Slade and Watson, 2006</xref>; <xref ref-type="bibr" rid="bibr131-0269881110372818">Vollebergh et al., 2001</xref>) have independently reported that panic disorder, agoraphobia, social phobia and specific phobia load together on one factor. <xref ref-type="bibr" rid="bibr132-0269881110372818">Watson (2005)</xref> has termed these the ‘fear disorders’. In contrast, generalized anxiety disorder is reported as loading on a separate factor together with depressive disorders. This has led to proposals that the above ‘fear disorders’ be categorized separately from generalized anxiety disorder in future classification. We have restricted the focus of this paper to the ‘fear disorders’, with emphasis on panic disorder and social phobia for which neurobiology has been particularly well studied in adults. In children, however, these disorders are less consistently identified, and some studies employ more diffuse groupings, including individuals with non-specific anxiety symptoms or with childhood-specific related conditions such as separation anxiety disorder. Therefore, we have broadened the scope of this paper to include studies with these wider inclusion criteria.</p>
<p>Regarding neurobiological approaches, biological models for panic disorder in adults have been of increasing interest during the last two decades (<xref ref-type="bibr" rid="bibr51-0269881110372818">Griez and Schruers, 1998</xref>; <xref ref-type="bibr" rid="bibr46-0269881110372818">Gorman et al., 1988</xref>; <xref ref-type="bibr" rid="bibr71-0269881110372818">Klein, 1994</xref>; <xref ref-type="bibr" rid="bibr73-0269881110372818">Krystal et al., 1996</xref>). SAnD has been less widely studied relative to panic disorder (<xref ref-type="bibr" rid="bibr12-0269881110372818">Bell et al., 1999</xref>; <xref ref-type="bibr" rid="bibr89-0269881110372818">Nutt et al., 1998</xref>; <xref ref-type="bibr" rid="bibr118-0269881110372818">Tancer, 1993</xref>). Challenge tests and neurotransmitter manipulation in adults such as administration of CO<sub>2</sub>, sodium lactate, caffeine, clonidine, yohimbine, isoprotenerol, cholecystokinin/pentagastrin, orthostatic challenge and tryptophan depletion have contributed to the delineation of the biological basis of both panic disorder (<xref ref-type="bibr" rid="bibr117-0269881110372818">Swain et al., 2003</xref>) and SAnD (<xref ref-type="bibr" rid="bibr113-0269881110372818">Stein and de Boer, 1999</xref>). Respiratory, cardiovascular, hypothalamic–pituitary–adrenal (HPA) abnormalities and psychological measures are among the outcomes studied as endpoints.</p>
<p>Some epidemiological studies suggest an increased risk of subsequent adult anxiety disorders in children with anxiety (<xref ref-type="bibr" rid="bibr95-0269881110372818">Pine et al., 1998a</xref>), as well as high rates of homotypic continuity (i.e. continuity of type over time) of anxiety disorders in children (<xref ref-type="bibr" rid="bibr36-0269881110372818">Ferdinand et al., 2007</xref>). Thus, some authors have suggested that children and adults may be better viewed as one group where there is a longitudinal continuity in anxiety disorders (<xref ref-type="bibr" rid="bibr70-0269881110372818">Kim-Cohen et al., 2003</xref>; <xref ref-type="bibr" rid="bibr83-0269881110372818">Maughan and Kim-Cohen, 2005</xref>; <xref ref-type="bibr" rid="bibr103-0269881110372818">Rutter et al., 2006</xref>). A study by Hayward and colleagues gives further support to a developmental model, noting that anxiety disorders existing since infancy commonly continue into adulthood (<xref ref-type="bibr" rid="bibr57-0269881110372818">Hayward et al., 2008</xref>). However, other works such as that of <xref ref-type="bibr" rid="bibr50-0269881110372818">Gregory et al. (2007)</xref> noted a lack of specificity in developmental histories of adults with anxiety disorders and strong co-morbidities between the disorders, but nevertheless called for more work to target the aetiology of anxiety disorders early in life. <xref ref-type="bibr" rid="bibr29-0269881110372818">Copeland et al. (2009)</xref> examined data from a population-based longitudinal study, concluding that a homotypic prediction from childhood or adolescent disorders to those in young adulthood was supported for anxiety disorders, but this was primarily accounted for by overanxious disorder, with varied results being reported on the homotypic prediction of other anxiety disorders. Thus overall, the issue of the extent to which anxiety disorders in children predict those in adults has yet to be resolved, a conclusion which underlines the need to understand the neurobiological similarities and differences between children and adults with anxiety disorders.</p>
<sec id="section2-0269881110372818">
<title>CO<sub>2</sub> challenges</title>
<p>In adults, CO<sub>2</sub> challenges have been well studied in panic disorder. There are two distinct paradigms: the low-dose and high-dose CO<sub>2</sub> challenge. The low-dose CO<sub>2</sub> challenge, whereby 5–7.5% CO<sub>2</sub> mixture is breathed for 10–20 minutes (<xref ref-type="bibr" rid="bibr46-0269881110372818">Gorman et al., 1988</xref>) produces replicable effects on respiratory outcomes and psychological endpoints such as the provocation of panic attacks in adult patients with panic disorder. Evidence regarding cardiovascular response to low-dose CO<sub>2</sub> in adults is conflicting, with some studies reporting elevated baseline and post- CO<sub>2</sub> cardiovascular measures (<xref ref-type="bibr" rid="bibr6-0269881110372818">Bailey et al., 2005</xref>) and others stating no differences (<xref ref-type="bibr" rid="bibr23-0269881110372818">Bystritsky et al., 2000</xref>; <xref ref-type="bibr" rid="bibr47-0269881110372818">Gorman et al., 1990</xref>). The response to CO<sub>2</sub> in adult SAnD models has been less frequently studied, being mostly used as a control for studies of adult panic disorder (<xref ref-type="bibr" rid="bibr24-0269881110372818">Caldirola et al., 1997</xref>; <xref ref-type="bibr" rid="bibr47-0269881110372818">Gorman et al., 1990</xref>; <xref ref-type="bibr" rid="bibr90-0269881110372818">Papp et al., 1993</xref>). To our knowledge, there are no data of adult models of cardiovascular activity in SAnD under low-dose CO<sub>2</sub>. Adult panic disorder studies have found no increase in cortisol levels over baseline on low-dose CO<sub>2</sub> challenge (<xref ref-type="bibr" rid="bibr110-0269881110372818">Sinha et al., 1999</xref>), but cortisol response to low-dose CO<sub>2</sub> has not been tested in adults with SAnD.</p>
<p>A different approach to the CO<sub>2</sub> challenge involves a 35% CO<sub>2</sub> single or double vital capacity breath (<xref ref-type="bibr" rid="bibr52-0269881110372818">Griez et al., 1990</xref>; <xref ref-type="bibr" rid="bibr91-0269881110372818">Perna et al., 1995</xref>), This ‘high-dose’ CO<sub>2</sub> challenge has been used widely in adults with panic disorder, employing a variety of outcomes including those relating to the respiratory system, psychological outcomes (<xref ref-type="bibr" rid="bibr41-0269881110372818">Fyer et al., 1987</xref>; <xref ref-type="bibr" rid="bibr128-0269881110372818">Van den Hout and Griez, 1984</xref>), the cardiovascular system (<xref ref-type="bibr" rid="bibr127-0269881110372818">Van den Hout and Griez, 1982</xref>) and the HPA axis (<xref ref-type="bibr" rid="bibr129-0269881110372818">Van Duinen et al., 2004</xref>, <xref ref-type="bibr" rid="bibr130-0269881110372818">2007</xref>). Respiratory and psychological outcomes have been examined using 35% CO<sub>2</sub> in SAnD (<xref ref-type="bibr" rid="bibr24-0269881110372818">Caldirola et al., 1997</xref>; <xref ref-type="bibr" rid="bibr47-0269881110372818">Gorman et al., 1990</xref>; <xref ref-type="bibr" rid="bibr90-0269881110372818">Papp et al., 1993</xref>), although the threshold for induction of panic attacks may be higher than in panic disorder.</p>
</sec>
<sec id="section3-0269881110372818">
<title>Noradrenergic/adrenergic challenges</title>
<p>A considerable body of evidence has accumulated in adults with panic disorder from studies involving adrenergic or noradrenergic neurotransmitter manipulation, for example with clonidine and yohimbine. For SAnD the evidence is less robust. Blunted growth hormone (GH) response to clonidine (<xref ref-type="bibr" rid="bibr21-0269881110372818">Brambilla et al., 1995b</xref>; <xref ref-type="bibr" rid="bibr27-0269881110372818">Charney et al., 1992</xref>; <xref ref-type="bibr" rid="bibr88-0269881110372818">Nutt, 1989</xref>; <xref ref-type="bibr" rid="bibr120-0269881110372818">Tancer et al., 1993</xref>; <xref ref-type="bibr" rid="bibr126-0269881110372818">Uhde et al., 1986</xref>, <xref ref-type="bibr" rid="bibr125-0269881110372818">1992</xref>), blunted cortisol response to clonidine (<xref ref-type="bibr" rid="bibr20-0269881110372818">Brambilla et al., 1995a</xref>), greater falls in systolic and diastolic blood pressure in response to clonidine (<xref ref-type="bibr" rid="bibr88-0269881110372818">Nutt, 1989</xref>) and a decrease in plasma noradrenaline in response to clonidine (<xref ref-type="bibr" rid="bibr27-0269881110372818">Charney et al., 1992</xref>) have been reported in adult panic disorder. Studies in adults with panic disorder also show blunted GH response to yohimbine (<xref ref-type="bibr" rid="bibr53-0269881110372818">Gurguis and Uhde, 1990</xref>; <xref ref-type="bibr" rid="bibr54-0269881110372818">Gurguis et al., 1997</xref>, <xref ref-type="bibr" rid="bibr125-0269881110372818">Uhde et al., 1992</xref>). Evidence in adults also supports abnormalities in response to orthostatic challenge in panic disorder and SAnD (<xref ref-type="bibr" rid="bibr115-0269881110372818">Stein et al., 1992</xref>). Adults with SAnD may have a similar degree of blunted GH response to clonidine and to growth hormone-releasing hormone (GHRH) as adults with panic disorder, but there evidence is more limited (<xref ref-type="bibr" rid="bibr120-0269881110372818">Tancer et al., 1993</xref>). <xref ref-type="bibr" rid="bibr100-0269881110372818">Potts et al. (1996)</xref> reported that a crossover study involving intravenous administration of yohimbine or placebo to six adults with SAnD led to a marked increase in social anxiety, correlating with an increase in plasma levels of MHPG, the main noradrenaline metabolite. There are no robust studies involving plasma noradrenaline response to clonidine in panic disorder or SAnD in adults.</p>
<p>Orthostatic challenge has also been used to examine catecholaminergic function in anxiety disorder. For example, adults with SAnD and panic disorder, and healthy controls were subjected to orthostatic challenge (<xref ref-type="bibr" rid="bibr115-0269881110372818">Stein et al., 1992</xref>). Those with SAnD had significantly greater noradrenaline plasma concentration before and after the challenge. However, a further study using a similar challenge in adults with SAnD did not report significant differences from controls (<xref ref-type="bibr" rid="bibr112-0269881110372818">Stein et al., 1994</xref>).</p>
</sec>
<sec id="section4-0269881110372818">
<title>Serotonergic challenges</title>
<p>Serotonergic function (5-HT) has been implicated in the mediation of fear and anxiety in animal and clinical human adult studies (<xref ref-type="bibr" rid="bibr13-0269881110372818">Bell and Nutt, 1998</xref>), resulting into a widespread use of serotonergic treatments in anxiety disorders (<xref ref-type="bibr" rid="bibr7-0269881110372818">Baldwin et al., 2005</xref>; <xref ref-type="bibr" rid="bibr8-0269881110372818">Ballenger, 1984</xref>). Fenfluramine is known to both increase serotonin release and inhibit reuptake (<xref ref-type="bibr" rid="bibr104-0269881110372818">Rowland and Carlton, 1986</xref>). It is associated with the provocation of anxiety symptoms and panic attacks in adults with panic disorder (<xref ref-type="bibr" rid="bibr121-0269881110372818">Targum and Marshall, 1989</xref>). In SAnD, fenfluramine has been associated with a greater cortisol response than in controls (<xref ref-type="bibr" rid="bibr119-0269881110372818">Tancer et al., 1994</xref>). Unfortunately, fenfluramine was withdrawn from most markets several years ago following reports of associated cardiac abnormalities, and is currently unavailable. mCPP (m-Chlorophenylpiperazine) is an agonist at some serotonin receptors and an antagonist at others, and also has antagonist activity at the alpha adrenoceptor. It provokes anxiety symptoms and panic attacks after intravenous infusion in people with panic disorder. Hollander et al. demonstrated a normal prolactin response but enhanced cortisol response to mCPP in subjects with social anxiety, especially marked in females (<xref ref-type="bibr" rid="bibr58-0269881110372818">Hollander et al., 1998</xref>).</p>
<p>Serotonin function may also be modified by tryptophan depletion, a technique involving large administration of neutral amino acids causing competitive inhibition of the entry into the brain of the serotonin precursor tryptophan (<xref ref-type="bibr" rid="bibr11-0269881110372818">Bell et al., 2005</xref>; <xref ref-type="bibr" rid="bibr60-0269881110372818">Hood et al., 2005</xref>). This leads to a transient depletion in tryptophan availability and therefore of serotonin. Adults with anxiety disorders, including panic disorder (<xref ref-type="bibr" rid="bibr10-0269881110372818">Bell et al., 2002</xref>) and SAnD (<xref ref-type="bibr" rid="bibr5-0269881110372818">Argyropoulos et al., 2004</xref>), may subsequently have exaggerated psychological and physical responses (<xref ref-type="bibr" rid="bibr31-0269881110372818">Davies et al., 2006</xref>) to chemical or psychological stress challenges under tryptophan depletion compared with the non-depleted state.</p>
</sec>
<sec id="section5-0269881110372818">
<title>Peptidergic challenges</title>
<p>CCK-4 is a peptide hormone and pentagstrin its synthetic analogue, which are agonists of the CCK-2 receptor. Both substances induce panic attacks in adults with panic disorder (<xref ref-type="bibr" rid="bibr19-0269881110372818">Bradwejn et al., 1990</xref>) and in SAnD (<xref ref-type="bibr" rid="bibr84-0269881110372818">McCann et al., 1997</xref>), albeit at a higher threshold, and not in all studies (<xref ref-type="bibr" rid="bibr65-0269881110372818">Katzman et al., 2004</xref>).</p>
</sec>
<sec id="section6-0269881110372818">
<title>Non-specific modulators</title>
<p>Sodium lactate is panicogenic in adult panic disorder (<xref ref-type="bibr" rid="bibr78-0269881110372818">Liebowitz et al., 1984</xref>); it does not appear to be anxiogenic in individuals with SAnD (<xref ref-type="bibr" rid="bibr51-0269881110372818">Griez and Schruers, 1998</xref>; <xref ref-type="bibr" rid="bibr79-0269881110372818">Liebowitz et al., 1985</xref>). Other studies have shown that caffeine challenges are panicogenic in adults both with panic disorder (<xref ref-type="bibr" rid="bibr87-0269881110372818">Nardi et al., 2007</xref>, <xref ref-type="bibr" rid="bibr86-0269881110372818">2009</xref>) and with SAnD (<xref ref-type="bibr" rid="bibr86-0269881110372818">Nardi et al., 2009</xref>; <xref ref-type="bibr" rid="bibr119-0269881110372818">Tancer et al., 1994</xref>), although the panic attacks were phenomenologically distinct between disorders, and more reproducible in the performance social anxiety subtype. Both lactate and caffeine are thought to involve multiple transmitter systems and/or non-specific metabolic or neurovascular effects.</p>
</sec>
<sec id="section7-0269881110372818">
<title>HPA axis modulators and direct measurement</title>
<p>A small number of challenge studies in adults with panic disorder have employed direct neurohormonal challenges to the HPA axis. For example, there have been reports of blunted GH responses to GHRH (<xref ref-type="bibr" rid="bibr120-0269881110372818">Tancer et al., 1993</xref>). Using the dexamethasone suppression test to investigate the dynamics of cortisol secretion in patients with social anxiety disorder, Uhde et al. concluded that SAnD patients did not differ from normal controls (<xref ref-type="bibr" rid="bibr124-0269881110372818">Uhde et al., 1994</xref>). The same group demonstrated a similar negative result in patients with panic disorder (<xref ref-type="bibr" rid="bibr123-0269881110372818">Uhde et al., 1988</xref>).</p>
<p>Beyond challenge studies, there have been many studies in adults which have sought to perform direct measurements of salivary cortisol in adults. The results have, however, been inconsistent, with some studies reporting elevation in salivary cortisol or other measures of HPA axis activity at baseline before a challenge (<xref ref-type="bibr" rid="bibr105-0269881110372818">Roy-Byrne et al., 1986</xref>) or at rest (<xref ref-type="bibr" rid="bibr44-0269881110372818">Goldstein et al., 1987</xref>), but others reporting normal cortisol concentration (<xref ref-type="bibr" rid="bibr64-0269881110372818">Kathol et al., 1988</xref>; <xref ref-type="bibr" rid="bibr123-0269881110372818">Uhde et al., 1988</xref>) at rest or when the baseline period before a challenge is long (<xref ref-type="bibr" rid="bibr59-0269881110372818">Holsboer et al., 1987</xref>). A 24-h sampling study of adults with panic disorder suggested that while day-time cortisol may be normal there are elevations overnight. A study conducted in individuals with SAnD reported no abnormality in HPA activity in non-depressed SAnD individuals (<xref ref-type="bibr" rid="bibr12-0269881110372818">Bell et al., 1999</xref>).</p>
</sec>
</sec>
<sec id="section8-0269881110372818">
<title>Aims</title>
<p>The main purpose of this paper is to systematically review the existing literature contributing to the development of neurobiological models in clinical and non-clinical samples of children or adolescents with the anxiety disorders panic disorder or social phobia, or with non-specific anxiety symptoms, using any challenge test, or direct measures of HPA axis function. This paper therefore adopts a focused approach, as challenge tests and cortisol measurements have been of great utility in facilitating our understanding of anxiety disorders in adults, with the neurobiology of panic disorder and SAnD having been particularly well elucidated by these techniques. We were aware that these techniques had been used less in children with anxiety relative to the body of work in adults. We believe that a review of the current literature in children relating to these methods may be a timely step in promoting research into the neurobiology of childhood anxiety disorders. Inevitably this places a restriction in the paper’s scope, which does not extend, for instance, to techniques such as neuroimaging.</p>
</sec>
<sec id="section9-0269881110372818" sec-type="methods">
<title>Methods</title>
<sec id="section10-0269881110372818">
<title>Inclusion criteria</title>
<p>All clinical studies using any pharmacological challenge test or direct assessment of cortisol, conducted in populations of children or adolescents: (a) at least some of whom had panic disorder or SAnD; (b) having anxiety symptoms without formal diagnosis; or (c) having diagnoses of childhood-specific anxiety disorders which overlap diagnostically with adult panic disorder and/or social phobia, were eligible for inclusion in the review.</p>
</sec>
<sec id="section11-0269881110372818">
<title>Challenges and other neurobiological tests</title>
<p>Paradigms included in our search were challenges with low or high-dose CO<sub>2</sub>, clonidine, isoproterenol, yohimbine, orthostatic challenge, mCPP, fenfluramine, pentagastrin, cholecystokinin, sodium lactate and caffeine, as well as tryptophan depletion techniques. Studies involving direct assessment of HPA axis function were also considered.</p>
</sec>
<sec id="section12-0269881110372818">
<title>Search strategy</title>
<p>The computerized databases searched were Medline (1966 to March 2008), PsychINFO (1967 to March 2008), Cochrane Library (up to March 2008) and EMBASE (1980 to March 2008). The keywords searched were [children], [adolescent], [child], AND [anxiety], [panic] AND [challenge test], [carbon dioxide], [serotonergic system], [serotonin], [Mcpp], [flenfluramine], [trypthopan depletion], [noradrenergic system], [adrenaline], [noradrenaline] [clonidine], [yohimbine], [isoprotenerol], [hpa], [cortisol], [cholecystokinin], [pentagastrin], [sodium lactate], [caffeine], [neurobiology]. All abstracts in the English and Spanish languages were reviewed. Studies meeting inclusion criteria were located either by electronic sources or by library services. Hand searching of reference lists in relevant publications was also conducted.</p>
</sec>
</sec>
<sec id="section13-0269881110372818" sec-type="results">
<title>Results</title>
<p>We identified a total of 22 studies which met the criteria outlined above. These 22 relevant studies are listed in <xref ref-type="table" rid="table1-0269881110372818">Table 1</xref>.</p>
<table-wrap id="table1-0269881110372818" position="float">
<label>Table 1</label>
<caption><p>List of eligible studies</p></caption>
<graphic alternate-form-of="table1-0269881110372818" xlink:href="10.1177_0269881110372818-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left" colspan="4">Studies involving challenge tests</th>
</tr>
<tr>
<th align="left">Study</th>
<th align="left">Challenge tests</th>
<th align="left">Outcome related to challenge</th>
<th align="left">Characteristics of children with anxiety or depression</th>
</tr>
</thead>
<tbody>
<tr>
<td><xref ref-type="bibr" rid="bibr30-0269881110372818">Coplan et al. (2002)</xref><xref ref-type="table-fn" rid="table-fn1-0269881110372818">*</xref></td>
<td>Low-dose CO<sub>2</sub> and tilt test</td>
<td>Salivary cortisol, API, anxiety, BES</td>
<td>Anxiety and/or mood disorder</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr62-0269881110372818">Kagan et al. (1988)</xref><xref ref-type="table-fn" rid="table-fn1-0269881110372818">*</xref></td>
<td>Orthostatic challenge</td>
<td>Heart rate</td>
<td>Behavioural inhibition</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr85-0269881110372818">Monk et al. (2001)</xref></td>
<td>Low-dose CO<sub>2</sub></td>
<td>Heart rate, heart rate variability</td>
<td>Various anxiety disorder symptoms or diagnoses</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr96-0269881110372818">Pine et al. (1998b)</xref></td>
<td>Low-dose CO<sub>2</sub></td>
<td>Respiratory measures, API, panic attacks</td>
<td>Various anxiety disorder diagnoses</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr97-0269881110372818">Pine et al. (2000)</xref></td>
<td>Low-dose CO<sub>2</sub></td>
<td>Respiratory measures, API, panic attacks</td>
<td>Various anxiety disorder diagnoses</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr98-0269881110372818">Pine et al. (2005)</xref></td>
<td>Low-dose CO<sub>2</sub></td>
<td>Respiratory measures, API, panic attacks</td>
<td>Various anxiety disorders, some with parental panic disorder or depression</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr107-0269881110372818">Sallee et al. (1998)</xref><xref ref-type="table-fn" rid="table-fn1-0269881110372818">*</xref></td>
<td>Clonidine</td>
<td>Plasma prolactin/GH/cortisol, HR, BP, anxiety</td>
<td>Various anxiety disorder diagnoses</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr108-0269881110372818">Sallee et al. (2000a)</xref><xref ref-type="table-fn" rid="table-fn1-0269881110372818">*</xref></td>
<td>Fenfluramine</td>
<td>Plasma prolactin/GH/cortisol, HR, BP, anxiety</td>
<td>Various anxiety disorder diagnoses</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr109-0269881110372818">Sallee et al. (2000b)</xref><xref ref-type="table-fn" rid="table-fn1-0269881110372818">*</xref></td>
<td>Yohimbine</td>
<td>Plasma prolactin/GH/cortisol, HR, BP, anxiety</td>
<td>Various anxiety disorder diagnoses</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr122-0269881110372818">Terleph et al. (2006)</xref><xref ref-type="table-fn" rid="table-fn1-0269881110372818">*</xref></td>
<td>Low-dose CO<sub>2</sub></td>
<td>Salivary cortisol, API, panic attacks</td>
<td>Various anxiety disorder diagnoses</td>
</tr>
<tr>
<th align="left" colspan="4">Further Studies involving HPA axis parameter measurement</th>
</tr>
<tr>
<th align="left">Study</th>
<th align="left">Stressor</th>
<th align="left">Outcome relating to HPA axis</th>
<th align="left">Characteristics of children with anxiety or depression</th>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr3-0269881110372818">Akyuz et al. (1996)</xref></td>
<td>Dental cavitation treatment</td>
<td>Salivary cortisol</td>
<td>Anxiety related acutely to stressor</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr18-0269881110372818">Blomqvist et al. (2007)</xref></td>
<td>Dental treatment</td>
<td>Salivary cortisol</td>
<td>Anticipatory anxiety and anxiety related acutely to stressor</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr32-0269881110372818">Dorn et al. (2003)</xref></td>
<td>TSST</td>
<td>Salivary cortisol</td>
<td>Various anxiety disorder diagnoses</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr34-0269881110372818">Feder et al. (2004)</xref></td>
<td>None</td>
<td>Salivary cortisol</td>
<td>Various anxiety disorder diagnoses/depression ± co-morbid anxiety</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr39-0269881110372818">Forbes et al. (2006)</xref></td>
<td>None</td>
<td>Salivary cortisol</td>
<td>Various anxiety disorder diagnoses and/or major depression</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr42-0269881110372818">Gerra et al. (1992)</xref></td>
<td>Physical exercise</td>
<td>Plasma ACTH/cortisol</td>
<td>Anxiety related acutely to stressor</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr43-0269881110372818">Gerra et al. (2000)</xref></td>
<td>Mental arithmetic, Stroop, TSST</td>
<td>Plasma ACTH/cortisol</td>
<td>Various anxiety disorder diagnoses</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr48-0269881110372818">Granger et al. (1994)</xref></td>
<td>Parent–child conflict task</td>
<td>Salivary cortisol</td>
<td>Anxiety and/or depression symptoms</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr49-0269881110372818">Greaves-Lord et al. (2007)</xref></td>
<td>None</td>
<td>Salivary cortisol</td>
<td>Persistent or current anxiety disorder diagnoses</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr63-0269881110372818">Kallen et al. (2008)</xref></td>
<td>None</td>
<td>Salivary cortisol</td>
<td>Various anxiety disorder diagnoses</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr80-0269881110372818">Livingston and Martin-Cannici (1987)</xref></td>
<td>Dexamethosone</td>
<td>Plasma cortisol</td>
<td>Separation anxiety disorder</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr82-0269881110372818">Martel et al. (1999)</xref></td>
<td>TSST</td>
<td>Salivary cortisol</td>
<td>Social anxiety disorder</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0269881110372818">
<label>*</label>
<p>These six papers involving challenge tests additionally measured baseline salivary or plasma cortisol.</p></fn>
<fn id="table-fn2-0269881110372818">
<p>Abbreviations: ACTH: adrenocorticotropic hormone, API: Acute Panic Inventory, BES: Borg Exertion Scale, BP: blood pressure, GH: growth hormone, HPA: hypothalamic–pituitary–adrenal, HR: heart rate, TSST: Trier Social Stress Test.</p></fn>
</table-wrap-foot>
</table-wrap>
<sec id="section14-0269881110372818">
<title>CO<sub>2</sub> challenges</title>
<sec id="section15-0269881110372818">
<title>Low-dose carbon dioxide challenge test</title>
<p>Few low-dose CO<sub>2</sub> studies have been conducted in children. In those studies that have been undertaken, authors have considered similar endpoints to those in adult studies, mainly focusing on the respiratory and cardiovascular system, the HPA axis and psychological measures.</p>
<sec id="section16-0269881110372818">
<title>Respiratory system</title>
<p>Three clinical studies have studied respiratory outcomes in anxious children under low-dose CO<sub>2</sub> challenge (<xref ref-type="bibr" rid="bibr96-0269881110372818">Pine et al., 1998b</xref>, <xref ref-type="bibr" rid="bibr97-0269881110372818">2000</xref>, <xref ref-type="bibr" rid="bibr98-0269881110372818">2005</xref>), supporting the hypothesis of a role for suffocation cues in anxious children found in previous research (<xref ref-type="bibr" rid="bibr99-0269881110372818">Pine et al., 1994</xref>). Two were conducted in clinical samples of children with anxiety. In one study (total <italic>n</italic> = 104, 57 anxious children and 47 controls) (<xref ref-type="bibr" rid="bibr97-0269881110372818">Pine et al., 2000</xref>), children with anxiety had various diagnoses (identified using DSM-IV criteria) including separation anxiety disorder (<italic>n</italic> = 25), generalized anxiety disorder (<italic>n</italic> = 29), panic disorder (<italic>n</italic> = 9), and social phobia (<italic>n</italic> = 26), with considerable co-morbidity. Sample diagnoses in the other study (<xref ref-type="bibr" rid="bibr96-0269881110372818">Pine et al., 1998b</xref>) (total <italic>n</italic> = 35, 20 anxious children and 15 controls) again showed high rates of co-morbid disorders that included panic disorder (<italic>n</italic> = 6), separation anxiety disorder (<italic>n</italic> = 12), overanxious disorder (<italic>n</italic> = 7), SAnD (<italic>n</italic> = 6), major depression (<italic>n</italic> = 3), attention-deficit hyperactive disorder (<italic>n</italic> = 3) and conduct disorder (<italic>n</italic> = 1).</p>
<p>The same group conducted a study in a community-based group (<italic>n</italic> = 142, 45 with current anxiety diagnoses) to further examine CO<sub>2</sub> sensitivity in children at high and low risk of anxiety based on parental diagnoses (<xref ref-type="bibr" rid="bibr98-0269881110372818">Pine et al., 2005</xref>). Of 142 offspring at risk of anxiety, 24 were offspring of parents with panic disorder alone, 40 of parents with panic disorder and major depression, 52 of parents with only major depression and 26 of psychiatrically healthy parents. Within this group, 45 children (31.6%) met criteria for current anxiety disorders: 19 subjects had SAnD only, eight subjects had separation anxiety disorder only, three had generalized anxiety disorder only and 15 subjects had multiple anxiety disorders.</p>
<p>The main findings regarding baseline respiratory differences on room air in these clinical samples of children with anxiety relative to controls were significant larger minute ventilation, larger tidal volume and increased respiratory rate. Interestingly, no differences in baseline end-tidal CO<sub>2</sub> were found (<xref ref-type="bibr" rid="bibr96-0269881110372818">Pine et al., 1998b</xref>, <xref ref-type="bibr" rid="bibr97-0269881110372818">2000</xref>). Post-CO<sub>2</sub> respiratory changes showed a steeper mean respiratory rate slope (<xref ref-type="bibr" rid="bibr96-0269881110372818">Pine et al., 1998b</xref>, <xref ref-type="bibr" rid="bibr97-0269881110372818">2000</xref>, <xref ref-type="bibr" rid="bibr98-0269881110372818">2005</xref>) and when adjusted for age, higher end-tidal CO<sub>2</sub> volume and higher minute volume (<xref ref-type="bibr" rid="bibr96-0269881110372818">Pine et al., 1998b</xref>). However, in one study (<xref ref-type="bibr" rid="bibr98-0269881110372818">Pine et al., 2005</xref>), after adjustment for specific diagnosis, significant excess in CO<sub>2</sub> sensitivity was observed only in separation anxiety disorder. These authors also concluded there were no different respiration patterns between children at high or low familial risk of anxiety (<xref ref-type="bibr" rid="bibr98-0269881110372818">Pine et al., 2005</xref>).</p>
</sec>
<sec id="section17-0269881110372818">
<title>Cardiovascular system</title>
<p>Despite a growing interest in integrating cardiovascular outcomes and anxiety, only <xref ref-type="bibr" rid="bibr85-0269881110372818">Monk et al. (2001)</xref> have performed a study specifically to examine the effects of CO<sub>2</sub> challenge tests on the cardiovascular system in children (total <italic>n</italic> = 34, 22 with anxiety disorders and 12 controls). Diagnoses in the children studied included generalized anxiety disorder (<italic>n</italic> = 9), separation anxiety disorder (<italic>n</italic> = 4), SAnD (<italic>n</italic> = 8) and panic disorder (<italic>n</italic> = 9). After adjustment for age and sex, a significantly higher baseline heart rate was found in the anxious children, and a lower overall baseline heart rate variability. However, when data analysis was controlled for respiratory rate, heart rate variability was no longer significantly lower in this group. Both groups had increased heart rate on CO<sub>2</sub> administration. Changes in heart rate variability in response to CO<sub>2</sub> were reported to be lower in children with anxiety disorders than in controls, but this effect was thought to be confounded by changes in respiration on CO<sub>2</sub> challenge (<xref ref-type="bibr" rid="bibr85-0269881110372818">Monk et al., 2001</xref>).</p>
</sec>
<sec id="section18-0269881110372818">
<title>Psychological impact</title>
<p>Post-CO<sub>2</sub> changes in children include an increased frequency of panic attacks or panic symptoms. Some studies postulate that a robust anxiety disorder diagnosis may be the only predictor of induction of panic attacks on CO<sub>2</sub> challenge (<xref ref-type="bibr" rid="bibr96-0269881110372818">Pine et al., 1998b</xref>, <xref ref-type="bibr" rid="bibr97-0269881110372818">2000</xref>, <xref ref-type="bibr" rid="bibr98-0269881110372818">2005</xref>).</p>
</sec>
<sec id="section19-0269881110372818">
<title>HPA axis</title>
<p><xref ref-type="bibr" rid="bibr30-0269881110372818">Coplan et al. (2002)</xref> conducted a study in children with a total <italic>n</italic> = 98, 36 healthy controls and 62 children with anxiety disorders and/or depression. Of the 62 cases, 22 carried the diagnosis of separation anxiety disorder, 22 suffered from SAnD, 24 of ‘overanxious’ or generalized anxiety disorder, 17 of panic disorder and 22 of major depressive disorder. However, the design of this study was somewhat different from the others in that the 62 children with anxiety disorders and/or depression were retrospectively subdivided into those who had an anxiety response to low-dose CO<sub>2</sub> and those who did not. Subsequent analysis compares these CO<sub>2</sub>-sensitive cases with non-CO<sub>2</sub>-sensitive cases and with the controls. The CO<sub>2</sub>-sensitive case group were reported to have significantly higher baseline salivary cortisol concentrations and significantly greater salivary cortisol concentration post-CO<sub>2</sub> administration.</p>
<p><xref ref-type="bibr" rid="bibr122-0269881110372818">Terleph et al., (2006)</xref> argued that previous studies had not taken account of parental anxiety disorder diagnosis. Using the same group of children as discussed earlier in the study of <xref ref-type="bibr" rid="bibr98-0269881110372818">Pine et al. (2005)</xref>, who were subject to low-dose CO<sub>2</sub> challenge, they reported that anxiety in children predicted neither baseline cortisol levels nor cortisol response to CO<sub>2</sub> challenge. However, as in Coplan et al.’s 2002 study, the magnitude of anxiety response to CO<sub>2</sub> was associated with salivary cortisol levels during CO<sub>2</sub> administration, independent of parental diagnosis.</p>
</sec>
</sec>
<sec id="section20-0269881110372818">
<title>High-dose carbon dioxide challenge test</title>
<p>No high-dose CO<sub>2</sub> studies were identified in any sample of children with anxiety or with anxiety disorders.</p>
</sec>
</sec>
<sec id="section21-0269881110372818">
<title>Adrenergic/noradrenergic challenges</title>
<p>Challenge tests involving the alpha-2 adrenoceptor agonist clonidine have been mainly employed for children with depressive disorders (<xref ref-type="bibr" rid="bibr61-0269881110372818">Jensen and Garfinkel, 1990</xref>; <xref ref-type="bibr" rid="bibr101-0269881110372818">Puig-Antich et al., 1981</xref>; <xref ref-type="bibr" rid="bibr106-0269881110372818">Ryan et al., 1994</xref>), but there has been considerably less work in anxious children.</p>
<p><xref ref-type="bibr" rid="bibr107-0269881110372818">Sallee et al. (1998)</xref> conducted a study (<italic>n</italic> = 39, 24 with anxiety disorders and 15 controls) using clonidine and reported no blunting of GH response, GH concentration in the anxious group being significantly elevated compared with that of controls. Anxiety disorders diagnosed in this study included separation anxiety disorder (<italic>n</italic> = 15), generalized anxiety disorder (<italic>n</italic> = 7), obsessive–compulsive disorder (<italic>n</italic> = 9), panic disorder (<italic>n</italic> = 1) and SAnD (<italic>n</italic> = 2), with co-morbid secondary diagnoses of major depression in three patients and attention-deficit hyperactive disorder in four. The excess GH concentration in response to clonidine was most marked in the subgroup with obsessive–compulsive disorder. This study involved children with high rates of co-morbidity, half of the sample presenting with multiple anxiety diagnoses (<italic>n</italic> = 11). No further studies employing the clonidine challenge were identified in children with anxiety disorders. Sallee et al. conducted a further study using the yohimbine challenge test in a group of anxious children (total <italic>n</italic> = 32, anxious children <italic>n</italic> = 17, separation anxiety disorder <italic>n</italic> = 10, generalized anxiety disorder <italic>n</italic> = 5, obsessive–compulsive disorder <italic>n</italic> = 8, panic disorder <italic>n</italic> = 1, SAnD <italic>n</italic> = 1, co-morbid attention-hyperactive deficit disorder <italic>n</italic> = 4, co-morbid major depression <italic>n</italic> = 1 and 15 controls) finding significant blunted responses in GH in children with anxiety disorders (<xref ref-type="bibr" rid="bibr109-0269881110372818">Sallee et al., 2000b</xref>). Both studies also examined several other hormonal and cardiovascular response to the respective challenges, but no significant difference between children with anxiety disorders and controls was reported in response to challenge for cortisol, nor for heart rate or blood pressure. There was a significantly greater maximum response of prolactin to yohimbine, but not of cortisol in children with anxiety compared with controls (<xref ref-type="bibr" rid="bibr109-0269881110372818">Sallee et al., 2000b</xref>). However, a significant difference was not demonstrated on repeated measures analysis.</p>
<p><xref ref-type="bibr" rid="bibr62-0269881110372818">Kagan et al. (1988)</xref> stated that children with behavioural inhibition, a developmental precursor of anxiety disorders (<xref ref-type="bibr" rid="bibr16-0269881110372818">Biederman et al., 1990</xref>) including SAnD, showed a larger increase in mean heart rate and greater diastolic response when undergoing orthostatic challenge than uninhibited children. <xref ref-type="bibr" rid="bibr30-0269881110372818">Coplan et al. (2002)</xref> used the tilt test, a form of orthostatic challenge, in the study described earlier where children with anxiety disorders or depression were retrospectively divided into those who had or had not had an anxiety response to CO<sub>2</sub>. Those who had responded with anxiety to the low-dose CO<sub>2</sub> challenge were reported to have significantly higher salivary cortisol concentrations than the non-responders and compared with healthy controls, both prior to and after the tilt test.</p>
<p>No challenge studies using the peripheral beta receptor agonist isoprotenerol were identified in children with anxiety or anxiety disorders.</p>
</sec>
<sec id="section22-0269881110372818">
<title>Serotonergic challenges</title>
<p>The role of 5-HT in childhood anxiety is most readily demonstrated by the indirect evidence of the extensive use of selective serotonin reuptake inhibitors (SSRIs) (<xref ref-type="bibr" rid="bibr94-0269881110372818">pine, 2002</xref>), albeit with the concerns raised recently regarding propensity to suicidality in children and younger adults (<xref ref-type="bibr" rid="bibr38-0269881110372818">Food and Drug Administration, 2004</xref>).</p>
<p>Fenfluramine challenges had only limited use in studies on childhood anxiety, whereas they have been more frequently employed in samples of children with attention-deficit hyperactive disorder (<xref ref-type="bibr" rid="bibr56-0269881110372818">Halperin et al., 1994</xref>, <xref ref-type="bibr" rid="bibr55-0269881110372818">1997</xref>; <xref ref-type="bibr" rid="bibr92-0269881110372818">Pick et al., 1999</xref>; <xref ref-type="bibr" rid="bibr116-0269881110372818">Stoff et al., 1992</xref>). <xref ref-type="bibr" rid="bibr108-0269881110372818">Sallee et al. (2000a)</xref> conducted a study using fenfluramine in anxious children (total <italic>n</italic> = 38, 24 with anxiety disorders (separation anxiety disorder <italic>n</italic> = 13, generalized anxiety disorder <italic>n</italic> = 6, obsessive–compulsive disorder <italic>n</italic> = 12, panic disorder <italic>n</italic> = 1, SAnD <italic>n</italic> = 2) and 14 controls). Although there were no differences in the change in cortisol, GH or prolactin output on fenfluramine challenge, the increase in prolactin concentration was significantly higher in the obsessive–compulsive disorder subgroup than both the remaining children with anxiety disorders and the controls. Controls had significantly higher changes in the ‘tense/anxious’ item of the anxiety scale (visual analogue mood scale, VAMS) after fenfluramine, and cardiovascular responses revealed a significantly greater increase in systolic blood pressure for controls compared with anxious subjects (<xref ref-type="bibr" rid="bibr108-0269881110372818">Sallee et al., 2000a</xref>).</p>
<p>No challenge studies using either tryptophan depletion techniques or challenges with the non-selective 5-HT receptor agonist mCPP were identified in children.</p>
</sec>
<sec id="section23-0269881110372818">
<title>Peptidergic challenges</title>
<p>No clinical evidence was identified regarding use of the peptidergic CCK-B receptor agonists pentagastrin and CCK-4 in children with anxiety or anxiety disorders.</p>
</sec>
<sec id="section24-0269881110372818">
<title>Other non-specific challenges</title>
<p>No evidence was identified relating to the use of sodium lactate or caffeine challenges in children with anxiety or anxiety disorders.</p>
</sec>
<sec id="section25-0269881110372818">
<title>Further studies assessing HPA axis function</title>
<p>In the low-dose CO<sub>2</sub> challenge studies discussed earlier, <xref ref-type="bibr" rid="bibr30-0269881110372818">Coplan et al. (2002)</xref> and <xref ref-type="bibr" rid="bibr122-0269881110372818">Terleph et al. (2006)</xref> reported that salivary cortisol concentrations during or after the CO<sub>2</sub> challenge were greater in children with anxiety disorders or depression who had an anxiety response to the challenge. Coplan et al.’s study also reported greater baseline salivary cortisol in the children with anxiety or depression who had responded to the CO<sub>2</sub> challenge.</p>
<p>Several studies have employed social stress challenges to examine the effect on HPA axis outcomes. The modified Trier Social Stress Test was used in a homogeneous sample of 27 girls with SAnD and 21 healthy controls (<xref ref-type="bibr" rid="bibr82-0269881110372818">Martel et al., 1999</xref>). There were no significant differences in salivary cortisol levels between cases and controls, both in baseline and post-stress measures. However, they reported increased levels during school days compared with non-school days across the sample (<xref ref-type="bibr" rid="bibr82-0269881110372818">Martel et al., 1999</xref>). <xref ref-type="bibr" rid="bibr32-0269881110372818">Dorn et al. (2003)</xref> found no significant difference in salivary cortisol levels before or after the Trier Social Stress Test between a group of 8–16-year-olds with clinical anxiety disorders and either matched subjects with recurrent abdominal pain or healthy controls. In a study which examined social anxiety symptoms (but not the diagnosis of SAnD), <xref ref-type="bibr" rid="bibr48-0269881110372818">Granger et al. (1994)</xref> reported that social anxiety symptoms predicted increased salivary cortisol response following a Parent–Child Conflict Discussion Task in 102 children aged 7–17 years referred to an outpatient clinic for behavioural and emotional problems.</p>
<p>Physical exercise (a 3–6 min aerobic stepping test) was applied to a group of healthy 14-year-old girls in an Italian high school sports team tested on day 4 of menstrual cycle, showing a significant increase in plasma adrenocorticotropic hormone (ACTH) concentration in subjects with at least subsyndromal anxiety (<xref ref-type="bibr" rid="bibr42-0269881110372818">Gerra et al., 1992</xref>). The same group subsequently examined 20 peripubertal anxious boys (including six with separation anxiety disorder) subjected to psychosocial stress tests including the Trier Social Stress Test, revealing some neurohormonal differences between this group and matched controls but no significant plasma cortisol or ACTH effects (<xref ref-type="bibr" rid="bibr43-0269881110372818">Gerra et al., 2000</xref>).</p>
<p>Dental anxiety is a naturalistic provocation in which salivary cortisol levels have been studied in children. Akyuz and colleagues reported an increase in the salivary cortisol of children associated with a dental cavitation treatment (<xref ref-type="bibr" rid="bibr3-0269881110372818">Akyuz et al., 1996</xref>). In contrast, a more recent study which included 71 13-year-old children as normal controls found that were no differences in cortisol levels before and after dental treatment; rather, the major stressor was anticipation of the dental experience (<xref ref-type="bibr" rid="bibr18-0269881110372818">Blomqvist et al., 2007</xref>), congruent with a report in adults (<xref ref-type="bibr" rid="bibr14-0269881110372818">Benjamins et al., 1992</xref>).</p>
<p>The dexamethasone suppression test has also been applied to children with anxiety disorders. In contrast to the lack of effect seen in adults suffering from SAnD as reported earlier, hospitalized prepubertal children with separation anxiety disorder who were similarly challenged did show higher levels of cortisol than hospitalized controls in one study (<xref ref-type="bibr" rid="bibr80-0269881110372818">Livingston and Martin-Cannici, 1987</xref>), albeit with no correlation with anxiety rating scores and without separation from children with major depression.</p>
<p>Several studies have been conducted in children to assess salivary cortisol concentration in the absence of a formal stressor. <xref ref-type="bibr" rid="bibr34-0269881110372818">Feder et al. (2004)</xref> conducted a study using a combination of data from two independent samples of children (total <italic>n</italic> = 124, anxious children <italic>n</italic> = 31, depressed children <italic>n</italic> = 76 (of which 47 had at least one co-morbid anxiety disorder) and controls <italic>n</italic> = 17). Disorders identified in the anxious children included separation anxiety disorder (<italic>n</italic> = 18), specific phobia (<italic>n</italic> = 18), generalized anxiety disorder (<italic>n</italic> = 4) and obsessive–compulsive disorder (<italic>n</italic> = 2). The study reported significant differences in 24-h salivary cortisol patterns between groups (<xref ref-type="bibr" rid="bibr34-0269881110372818">Feder et al., 2004</xref>). Post-hoc analyses of the night-time period data (9 pm to 8 am) showed significant differences in anxious children compared with other groups, with an early initial sluggish rise in salivary cortisol and a steeper rise in morning hours, suggesting an impairment in the sleep pattern in anxious children or central changes in corticotrophin releasing factor regulation (<xref ref-type="bibr" rid="bibr17-0269881110372818">Bierwolf et al., 1997</xref>; <xref ref-type="bibr" rid="bibr81-0269881110372818">Luboshitzky, 2000</xref>). During the day-time period there were also different salivary cortisol patterns in both anxious and depressed children in comparison with controls.</p>
<p><xref ref-type="bibr" rid="bibr39-0269881110372818">Forbes et al. (2006)</xref> also compared peri-sleep cortisol levels in children with anxiety disorders to other groups (total <italic>n</italic> = 138 children and 86 adolescents, 116 with major depression, 32 with anxiety disorders (generalized anxiety disorder <italic>n</italic> = 23), overanxious disorder <italic>n</italic> = 4, panic disorder <italic>n</italic> = 2, SAnD <italic>n</italic> = 1 and 76 controls), finding higher peri-sleep cortisol levels in the anxiety disorders group, but only in children, and not in adolescents. Similar results were reported in the group with depression (<xref ref-type="bibr" rid="bibr39-0269881110372818">Forbes et al., 2006</xref>).</p>
<p><xref ref-type="bibr" rid="bibr49-0269881110372818">Greaves-Lord et al. (2007)</xref> conducted a population-based study of 1768 children and reported an association between increased awakening salivary cortisol response in persistent, but not current anxiety disorders. Another recent study by Kallen et al. suggests that basal HPA axis activity in children with anxiety disorders (total <italic>n</italic> = 99, generalized anxiety disorder <italic>n</italic> = 33, separation anxiety disorder <italic>n</italic> = 24, SAnD <italic>n</italic> = 24, or specific phobia <italic>n</italic> = 18) is associated with scores on dimensional anxiety scales, but not with the DSM-IV diagnosis (<xref ref-type="bibr" rid="bibr63-0269881110372818">Kallen et al., 2008</xref>). Kagan et al. reported that unbound salivary cortisol levels in a further cohort of children with behavioural inhibition were correlated to the severity of inhibition (<xref ref-type="bibr" rid="bibr62-0269881110372818">Kagan et al., 1988</xref>).</p>
</sec>
</sec>
<sec id="section26-0269881110372818" sec-type="discussion">
<title>Discussion</title>
<p>This review has summarized evidence in neurobiological research on children with anxiety symptoms and anxiety disorders. Twenty-two studies conducted in children suffering from anxiety disorders or anxiety symptoms using neurobiological paradigms emerged.</p>
<p>It is notable that several of the challenge paradigms widely used in adult panic disorder and/or adult SAnD have never been employed in studies of anxious children. We also identified no studies in anxious children employing the 35% CO<sub>2</sub> challenge, nor challenge studies involving isoproterenol, pentagastrin, cholecystokinin, sodium lactate, caffeine, mCPP or tryptophan depletion, despite much research using these paradigms in adults. It is unclear why none of these latter approaches have been undertaken in children. This may of course reflect ethical considerations, in that it could be considered unreasonable to subject the anxious child to the further adverse experiences that could occur during a challenge test. Some paradigms may not be used because of the nature of the challenge; for example, use of the intravenous route of administration may be more difficult to justify in children than in adults. It is notable that in Pine et al.’s study (<xref ref-type="bibr" rid="bibr98-0269881110372818">2005</xref>) using a low-dose CO<sub>2</sub> paradigm, 35% of 220 children identified as meeting the entry criteria declined participation due to reservations about the CO<sub>2</sub> procedure. Single breath 35% (high-dose) CO<sub>2</sub> challenge may be a less acceptable paradigm. Nevertheless, if anxious children (especially those suffering from panic disorder or SAnD) had an adult SAnD-like CO<sub>2</sub> sensibility (placed between normal children and adult panic disorder individuals), its use may be particularly valuable in delineating the neurobiology of childhood anxiety disorders. The high-dose CO<sub>2</sub> challenge test has been of increasing interest in delineating adult main neurobiological models of different anxiety disorders, as panic disorder, SAnD or generalized anxiety disorder, but caveats remain as to its acceptability in younger children.</p>
<p>Whether insurmountable methodological barriers account for the present limited development of childhood models of anxiety is not yet clear. The lack of development of models for these disorders in children may be due to various reasons, not only the potential risks that may accrue to children through adverse consequences but also pre-existing prejudices that anxiety in younger people is relatively unimportant, and the increased level of technical difficulty and ethical issues in performing biological procedures in this population group (<xref ref-type="bibr" rid="bibr25-0269881110372818">Cartwright-Hatton, 2006</xref>; <xref ref-type="bibr" rid="bibr93-0269881110372818">Pine, 1999</xref>). Whatever the cause for the current limited development of models and applications of challenge tests in children with SAnD, panic disorder and other anxiety disorders, the widespread evidence for the existence of these disorders in children and the possibility they may continue into adulthood (<xref ref-type="bibr" rid="bibr9-0269881110372818">Balon et al., 1989</xref>; <xref ref-type="bibr" rid="bibr15-0269881110372818">Biederman et al., 2006</xref>; <xref ref-type="bibr" rid="bibr36-0269881110372818">Ferdinand et al., 2007</xref>; <xref ref-type="bibr" rid="bibr57-0269881110372818">Hayward et al., 2008</xref>; <xref ref-type="bibr" rid="bibr70-0269881110372818">Kim-Cohen et al., 2003</xref>; <xref ref-type="bibr" rid="bibr83-0269881110372818">Maughan and Kim-Cohen, 2005</xref>; <xref ref-type="bibr" rid="bibr95-0269881110372818">Pine et al., 1998a</xref>; <xref ref-type="bibr" rid="bibr103-0269881110372818">Rutter et al., 2006</xref>) means that consideration should be given to conducting further research in a safe, acceptable and reproducible manner.</p>
<p>Where studies have been performed, response to neurobiological challenges in childhood anxiety was often similar to those present in adult anxiety disorders, such as panic disorder and SAnD. However, current evidence also suggests that anxious children differ from adults in some aspects of their responses to challenge tests.</p>
<p>First, children may experience panic attacks less frequently under low-dose CO<sub>2</sub> challenge than adults, but this may explained by diagnostic heterogeneity, with only a proportion of children having a specific panic disorder diagnosis in the populations studied, whereas similar studies in adults may be conducted entirely in patients with panic disorder who will have the lowest threshold for experiencing panic in response to CO<sub>2</sub>. In addition, Pine et al.’s first study (<xref ref-type="bibr" rid="bibr96-0269881110372818">1998b</xref>) employed 3% CO<sub>2</sub> in the first few cases for safety reasons, and this may have reduced the likelihood of spontaneous panic. It is also possible that the disparity is due to differences in CO<sub>2</sub> dynamics between adults and children (<xref ref-type="bibr" rid="bibr96-0269881110372818">Pine et al., 1998b</xref>). Furthermore, although respiratory outcomes both on air and on low-dose CO<sub>2</sub> in children with anxiety (<xref ref-type="bibr" rid="bibr96-0269881110372818">Pine et al., 1998b</xref>) were similar to data from low-dose CO<sub>2</sub> studies conducted in adult panic disorder samples (<xref ref-type="bibr" rid="bibr46-0269881110372818">Gorman et al., 1988</xref>; <xref ref-type="bibr" rid="bibr90-0269881110372818">Papp et al., 1993</xref>), there were some outcomes for which anxious children, unlike adults with panic disorder, did not differ from controls. Notably, end-tidal CO<sub>2</sub> on air did not differ between children with anxiety and controls, although minute ventilation was significantly different. <xref ref-type="bibr" rid="bibr96-0269881110372818">Pine et al. (1998b)</xref> suggest that there may be an overproduction or less efficient handling of CO<sub>2</sub> in children with anxiety disorders compared with adults.</p>
<p>Second, while several studies reported blunted GH and cortisol responses to clonidine in adult panic disorder (<xref ref-type="bibr" rid="bibr21-0269881110372818">Brambilla et al., 1995b</xref>; <xref ref-type="bibr" rid="bibr27-0269881110372818">Charney et al., 1992</xref>; <xref ref-type="bibr" rid="bibr88-0269881110372818">Nutt, 1989</xref>; <xref ref-type="bibr" rid="bibr120-0269881110372818">Tancer et al., 1993</xref>; <xref ref-type="bibr" rid="bibr126-0269881110372818">Uhde et al., 1986</xref>, <xref ref-type="bibr" rid="bibr125-0269881110372818">1992</xref>) and other adult anxiety disorders (<xref ref-type="bibr" rid="bibr1-0269881110372818">Abelson et al., 1991</xref>), by contrast <xref ref-type="bibr" rid="bibr107-0269881110372818">Sallee et al. (1998)</xref> reported no blunting of GH response to clonidine in children with anxiety disorders, the effect being significantly elevated compared with controls. Certain panic disorder models in adults have postulated super-sensitivity of certain noradrenergic adrenoreceptors and sub-sensitivity of others (<xref ref-type="bibr" rid="bibr88-0269881110372818">Nutt, 1989</xref>). Adult models for panic disorder and SAnD suggest central postsynaptic alpha-2 adrenoceptor sub-sensitivity due to an alpha-2 adrenoceptor down-regulation. <xref ref-type="bibr" rid="bibr107-0269881110372818">Sallee et al. (1998)</xref> suggested that their results may indicate that adrenergic postsynaptic receptor down-regulation is not a feature of childhood anxiety and that enhanced central adrenergic sensitivity in anxiety would argue against a neurobiological continuum from childhood to adult anxiety disorder. However, in a subset of the same group of children with anxiety disorders, the same group did find effects of yohimbine challenge in terms of GH response, comparable to those in adults with panic disorder (<xref ref-type="bibr" rid="bibr22-0269881110372818">Bremner et al., 1996</xref>; <xref ref-type="bibr" rid="bibr125-0269881110372818">Uhde et al., 1992</xref>). Taken together, these findings require a more complex model of the biology of childhood anxiety to explain. <xref ref-type="bibr" rid="bibr109-0269881110372818">Sallee et al. (2000b)</xref> speculated that the overactive noradrenergic system postulated earlier may not be accompanied by alpha-2 adrenoceptor down-regulation but longitudinal studies would be required to examine whether alpha 2 adrenoceptor down-regulation develops with age.</p>
<p>Thirdly, in tests of serotonergic neurotransmission, <xref ref-type="bibr" rid="bibr108-0269881110372818">Sallee et al. (2000a)</xref> reported a similar blunted prolactin response to fenfluramine in children with anxiety disorders other than obsessive–compulsive disorder. Conversely, prolactin blunting has been reported in adults with obsessive–compulsive disorder but not tested in other adult anxiety disorders. Unlike in adults with panic disorder, children with anxiety disorders did not experience excess anxiety after fenfluramine, but the control group of children exhibited significantly increased anxiety ratings. As with the noradrenergic challenge tests above, the authors postulate that there may be biological differences between early and late childhood anxiety which extend to the serotonergic system.</p>
<p>Studies involving HPA axis measurement appear overall to produce more consistent evidence of HPA axis abnormalities in children with anxiety than in the corresponding body of evidence for adults, but there are exceptions (<xref ref-type="bibr" rid="bibr32-0269881110372818">Dorn et al., 2003</xref>; <xref ref-type="bibr" rid="bibr43-0269881110372818">Gerra et al., 2000</xref>; <xref ref-type="bibr" rid="bibr82-0269881110372818">Martel et al., 1999</xref>). It is possible that studies in children may have been influenced by the evolution of the literature in adults, which has led to an increasing understanding of factors which need to be controlled for when assessing HPA axis function. For instance, it is notable that some of the studies in children focused specifically on cortisol in the night-time period, since studies in adults (<xref ref-type="bibr" rid="bibr2-0269881110372818">Abelson et al., 2007</xref>) had previously suggested that this was the time that a difference between cortisol concentrations in panic disorder and healthy controls might be most readily observed.</p>
<p>Where studies have been performed in children with anxiety there are a number of limitations. In only one paper, Martel et al.’s study of children with SAnD (<xref ref-type="bibr" rid="bibr82-0269881110372818">Martel et al., 1999</xref>), had a group of children with a homogenous diagnosis of either panic disorder or social phobia studied. We noted that clinical research in children with anxiety has mainly been conducted using heterogeneous samples containing children with a variety of different anxiety disorders, often including the ‘fear disorders’ and also generalized anxiety disorder and other diagnoses, despite the fact that many paradigms in adult anxiety disorders have yielded different results for adults with fear-based disorders compared with those for generalized anxiety disorder. One reason for this is that co-morbidity is frequent. Although co-morbid diagnoses are common, studying childhood anxiety using heterogeneous samples creates difficulties in delineating models, as adult models are usually derived from diagnostically homogeneous samples. Therefore, it is our belief that it is preferable to avoid conducting studies where adequate power can only be achieved by including children with multiple heterogeneous anxiety disorders. In addition, broad age ranges within groups studied may have led to heterogeneity in some studies. Clinical experience and evidence-based data suggest that anxiety in pre-school age children (0–5 years old) may differ from symptom patterns in older children (6–12 years) and again in adolescents (age 13–18), and these differences may lead to inconsistencies in biological response when an excessively broad age range is studied.</p>
<p>We remain uncertain as to whether differences in the biology of anxiety disorders between children and adults are merely a consequence of chronicity experienced by many adults entering research studies. It is possible that chronicity induces changes which underlie the observed differences between adults and children. Further research is needed to elucidate this issue, with greater emphasis on prospective longitudinal studies in anxiety following individuals from childhood to adulthood and examining any alterations in their clinical presentation, relevant biological markers and appropriate challenge tests.</p>
<p>In conclusion, further development of the database of studies relating to anxiety disorders in children using the techniques described in this paper is required. There is a need to consider the merit of studying specific diagnoses, or at least biologically related groups of diagnoses, and extending the limited range of relevant challenges and other neurobiological tests used in this population.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="bibr1-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Abelson</surname><given-names>JL</given-names></name>
<name><surname>Glitz</surname><given-names>D</given-names></name>
<name><surname>Cameron</surname><given-names>OG</given-names></name>
<name><surname>Lee</surname><given-names>MA</given-names></name>
<name><surname>Bronzo</surname><given-names>M</given-names></name>
<name><surname>Curtis</surname><given-names>GC</given-names></name>
</person-group> (<year>1991</year>) <article-title>Blunted growth hormone response to clonidine in patients with generalized anxiety disorder</article-title>. <source>Arch Gen Psychiatry</source> <volume>48</volume>: <fpage>157</fpage>–<lpage>162</lpage>.</citation>
</ref>
<ref id="bibr2-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Abelson</surname><given-names>JL</given-names></name>
<name><surname>Khan</surname><given-names>S</given-names></name>
<name><surname>Liberzon</surname><given-names>I</given-names></name>
</person-group> (<year>2007</year>) <article-title>HPA axis activity in patients with panic disorder: review and synthesis of four studies</article-title>. <source>Depress Anxiety</source> <volume>24</volume>: <fpage>66</fpage>–<lpage>76</lpage>.</citation>
</ref>
<ref id="bibr3-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Akyuz</surname><given-names>S</given-names></name>
<name><surname>Pince</surname><given-names>S</given-names></name>
<name><surname>Hekin</surname><given-names>N</given-names></name>
</person-group> (<year>1996</year>) <article-title>Children’s stress during a restorative dental treatment: assessment using salivary cortisol measurements</article-title>. <source>J Clin Pediatr Dent</source> <volume>20</volume>: <fpage>219</fpage>–<lpage>223</lpage>.</citation>
</ref>
<ref id="bibr4-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Andrews</surname><given-names>G</given-names></name>
<name><surname>Anderson</surname><given-names>TM</given-names></name>
<name><surname>Slade</surname><given-names>T</given-names></name>
<name><surname>Sunderland</surname><given-names>M</given-names></name>
</person-group> (<year>2008</year>) <article-title>Classification of anxiety and depressive disorders: problems and solutions</article-title>. <source>Depress Anxiety</source> <volume>25</volume>: <fpage>274</fpage>–<lpage>281</lpage>.</citation>
</ref>
<ref id="bibr5-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Argyropoulos</surname><given-names>SV</given-names></name>
<name><surname>Hood</surname><given-names>SD</given-names></name>
<name><surname>Adrover</surname><given-names>M</given-names></name>
<etal/>
</person-group>. (<year>2004</year>) <article-title>Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorder</article-title>. <source>Biol Psychiatry</source> <volume>56</volume>: <fpage>503</fpage>–<lpage>509</lpage>.</citation>
</ref>
<ref id="bibr6-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bailey</surname><given-names>JE</given-names></name>
<name><surname>Argyropoulos</surname><given-names>SV</given-names></name>
<name><surname>Kendrick</surname><given-names>AH</given-names></name>
<name><surname>Nutt</surname><given-names>DJ</given-names></name>
</person-group> (<year>2005</year>) <article-title>Behavioral and cardiovascular effects of 7.5% CO<sub>2</sub> in human volunteers</article-title>. <source>Depress Anxiety</source> <volume>21</volume>: <fpage>18</fpage>–<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr7-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baldwin</surname><given-names>DS</given-names></name>
<name><surname>Anderson</surname><given-names>IM</given-names></name>
<name><surname>Nutt</surname><given-names>DJ</given-names></name>
<etal/>
</person-group>. (<year>2005</year>) <article-title>Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. British Association for Psychopharmacology</article-title>. <source>J Psychopharmacol</source> <volume>19</volume>: <fpage>567</fpage>–<lpage>596</lpage>.</citation>
</ref>
<ref id="bibr8-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ballenger</surname><given-names>JC</given-names></name>
</person-group> (<year>1984</year>) <article-title>Psychopharmacology of the anxiety disorders</article-title>. <source>Psychiatr Clin North Am</source> <volume>7</volume>: <fpage>757</fpage>–<lpage>771</lpage>.</citation>
</ref>
<ref id="bibr9-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Balon</surname><given-names>R</given-names></name>
<name><surname>Yeragani</surname><given-names>VK</given-names></name>
<name><surname>Pohl</surname><given-names>R</given-names></name>
</person-group> (<year>1989</year>) <article-title>Higher frequency of separation anxiety in panic disorder patients</article-title>. <source>Am J Psychiatry</source> <volume>146</volume>: <fpage>1351</fpage>.</citation>
</ref>
<ref id="bibr10-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bell</surname><given-names>C</given-names></name>
<name><surname>Forshall</surname><given-names>S</given-names></name>
<name><surname>Adrover</surname><given-names>M</given-names></name>
<etal/>
</person-group>. (<year>2002</year>) <article-title>Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine</article-title>. <source>J Psychopharmacol</source> <volume>16</volume>: <fpage>5</fpage>–<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr11-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bell</surname><given-names>CJ</given-names></name>
<name><surname>Hood</surname><given-names>SD</given-names></name>
<name><surname>Nutt</surname><given-names>DJ</given-names></name>
</person-group> (<year>2005</year>) <article-title>Acute tryptophan depletion. Part II: clinical effects and implications</article-title>. <source>Aust N Z J Psychiatry</source> <volume>39</volume>: <fpage>565</fpage>–<lpage>574</lpage>.</citation>
</ref>
<ref id="bibr12-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bell</surname><given-names>CJ</given-names></name>
<name><surname>Malizia</surname><given-names>AL</given-names></name>
<name><surname>Nutt</surname><given-names>DJ</given-names></name>
</person-group> (<year>1999</year>) <article-title>The neurobiology of social phobia</article-title>. <source>Eur Arch Psychiatry Clin Neurosci</source> <volume>249</volume>(<issue>suppl 1</issue>): <fpage>S11</fpage>–<lpage>18</lpage>.</citation>
</ref>
<ref id="bibr13-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bell</surname><given-names>CJ</given-names></name>
<name><surname>Nutt</surname><given-names>DJ</given-names></name>
</person-group> (<year>1998</year>) <article-title>Serotonin and panic</article-title>. <source>Br J Psychiatry</source> <volume>72</volume>: <fpage>465</fpage>–<lpage>471</lpage>.</citation>
</ref>
<ref id="bibr14-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Benjamins</surname><given-names>C</given-names></name>
<name><surname>Asscheman</surname><given-names>H</given-names></name>
<name><surname>Schuurs</surname><given-names>AH</given-names></name>
</person-group> (<year>1992</year>) <article-title>Increased salivary cortisol in severe dental anxiety</article-title>. <source>Psychophysiology</source> <volume>29</volume>: <fpage>302</fpage>–<lpage>305</lpage>.</citation>
</ref>
<ref id="bibr15-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Biederman</surname><given-names>J</given-names></name>
<name><surname>Petty</surname><given-names>CR</given-names></name>
<name><surname>Faraone</surname><given-names>SV</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Antecedents to panic disorder in nonreferred adults</article-title>. <source>J Clin Psychiatry</source> <volume>67</volume>: <fpage>1179</fpage>–<lpage>1186</lpage>.</citation>
</ref>
<ref id="bibr16-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Biederman</surname><given-names>J</given-names></name>
<name><surname>Rosenbaum</surname><given-names>JF</given-names></name>
<name><surname>Hirshfeld</surname><given-names>DR</given-names></name>
<etal/>
</person-group>. (<year>1990</year>) <article-title>Psychiatric correlates of behavioral inhibition in young children of parents with and without psychiatric disorders</article-title>. <source>Arch Gen Psychiatry</source> <volume>47</volume>: <fpage>21</fpage>–<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr17-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bierwolf</surname><given-names>C</given-names></name>
<name><surname>Struve</surname><given-names>K</given-names></name>
<name><surname>Marshall</surname><given-names>L</given-names></name>
<name><surname>Born</surname><given-names>J</given-names></name>
<name><surname>Fehm</surname><given-names>HL</given-names></name>
</person-group> (<year>1997</year>) <article-title>Slow wave sleep drives inhibition of pituitary-adrenal secretion in humans</article-title>. <source>J Neuroendocrinol</source> <volume>9</volume>: <fpage>479</fpage>–<lpage>484</lpage>.</citation>
</ref>
<ref id="bibr18-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Blomqvist</surname><given-names>M</given-names></name>
<name><surname>Holmberg</surname><given-names>K</given-names></name>
<name><surname>Lindblad</surname><given-names>F</given-names></name>
<name><surname>Fernell</surname><given-names>E</given-names></name>
<name><surname>Ek</surname><given-names>U</given-names></name>
<name><surname>Dahllof</surname><given-names>G</given-names></name>
</person-group> (<year>2007</year>) <article-title>Salivary cortisol levels and dental anxiety in children with attention deficit hyperactivity disorder</article-title>. <source>Eur J Oral Sci</source> <volume>115</volume>: <fpage>1</fpage>–<lpage>6</lpage>.</citation>
</ref>
<ref id="bibr19-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bradwejn</surname><given-names>J</given-names></name>
<name><surname>Koszycki</surname><given-names>D</given-names></name>
<name><surname>Meterissian</surname><given-names>G</given-names></name>
</person-group> (<year>1990</year>) <article-title>Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder</article-title>. <source>Can J Psychiatry</source> <volume>35</volume>: <fpage>83</fpage>–<lpage>85</lpage>.</citation>
</ref>
<ref id="bibr20-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brambilla</surname><given-names>F</given-names></name>
<name><surname>Bellodi</surname><given-names>L</given-names></name>
<name><surname>Arancio</surname><given-names>C</given-names></name>
<name><surname>Nobile</surname><given-names>P</given-names></name>
<name><surname>Perna</surname><given-names>G</given-names></name>
</person-group> <year>1995a</year> <article-title>Alpha 2-adrenergic receptor sensitivity in panic disorder: II. Cortisol response to clonidine stimulation in panic disorder</article-title>. <source>Psychoneuroendocrinology</source> <volume>20</volume>: <fpage>11</fpage>–<lpage>19</lpage>.</citation>
</ref>
<ref id="bibr21-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brambilla</surname><given-names>F</given-names></name>
<name><surname>Perna</surname><given-names>G</given-names></name>
<name><surname>Garberi</surname><given-names>A</given-names></name>
<name><surname>Nobile</surname><given-names>P</given-names></name>
<name><surname>Bellodi</surname><given-names>L</given-names></name>
</person-group> (<year>1995b</year>) <article-title>Alpha 2-adrenergic receptor sensitivity in panic disorder: I. GH response to GHRH and clonidine stimulation in panic disorder</article-title>. <source>Psychoneuroendocrinology</source> <volume>20</volume>: <fpage>1</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr22-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bremner</surname><given-names>JD</given-names></name>
<name><surname>Krystal</surname><given-names>JH</given-names></name>
<name><surname>Southwick</surname><given-names>SM</given-names></name>
<name><surname>Charney</surname><given-names>DS</given-names></name>
</person-group> (<year>1996</year>) <article-title>Noradrenergic mechanisms in stress and anxiety: II. Clinical studies</article-title>. <source>Synapse</source> <volume>23</volume>: <fpage>39</fpage>–<lpage>51</lpage>.</citation>
</ref>
<ref id="bibr23-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bystritsky</surname><given-names>A</given-names></name>
<name><surname>Craske</surname><given-names>M</given-names></name>
<name><surname>Maidenberg</surname><given-names>E</given-names></name>
<name><surname>Vapnik</surname><given-names>T</given-names></name>
<name><surname>Shapiro</surname><given-names>D</given-names></name>
</person-group> (<year>2000</year>) <article-title>Autonomic reactivity of panic patients during a CO<sub>2</sub> inhalation procedure</article-title>. <source>Depress Anxiety</source> <volume>11</volume>: <fpage>15</fpage>–<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr24-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Caldirola</surname><given-names>D</given-names></name>
<name><surname>Perna</surname><given-names>G</given-names></name>
<name><surname>Arancio</surname><given-names>C</given-names></name>
<name><surname>Bertani</surname><given-names>A</given-names></name>
<name><surname>Bellodi</surname><given-names>L</given-names></name>
</person-group> (<year>1997</year>) <article-title>The 35% CO<sub>2</sub> challenge test in patients with social phobia</article-title>. <source>Psychiatry Res</source> <volume>71</volume>: <fpage>41</fpage>–<lpage>48</lpage>.</citation>
</ref>
<ref id="bibr25-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cartwright-Hatton</surname><given-names>S</given-names></name>
</person-group> (<year>2006</year>) <article-title>Anxiety of childhood and adolescence: Challenges and opportunities</article-title>. <source>Clin Psychol Rev</source> <volume>26</volume>: <fpage>813</fpage>–<lpage>816</lpage>.</citation>
</ref>
<ref id="bibr26-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cartwright-Hatton</surname><given-names>S</given-names></name>
<name><surname>McNicol</surname><given-names>K</given-names></name>
<name><surname>Doubleday</surname><given-names>E</given-names></name>
</person-group> (<year>2006</year>) <article-title>Anxiety in a neglected population: prevalence of anxiety disorders in pre-adolescent children</article-title>. <source>Clin Psychol Rev</source> <volume>26</volume>: <fpage>817</fpage>–<lpage>833</lpage>.</citation>
</ref>
<ref id="bibr27-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Charney</surname><given-names>DS</given-names></name>
<name><surname>Woods</surname><given-names>SW</given-names></name>
<name><surname>Krystal</surname><given-names>JH</given-names></name>
<name><surname>Nagy</surname><given-names>LM</given-names></name>
<name><surname>Heninger</surname><given-names>GR</given-names></name>
</person-group> (<year>1992</year>) <article-title>Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients</article-title>. <source>Acta Psychiatr Scand</source> <volume>86</volume>: <fpage>273</fpage>–<lpage>282</lpage>.</citation>
</ref>
<ref id="bibr28-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chavira</surname><given-names>DA</given-names></name>
<name><surname>Stein</surname><given-names>MB</given-names></name>
</person-group> (<year>2000</year>) <article-title>Recent developments in child and adolescent social phobia</article-title>. <source>Curr Psychiatry Rep</source> <volume>2</volume>: <fpage>347</fpage>–<lpage>352</lpage>.</citation>
</ref>
<ref id="bibr29-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Copeland</surname><given-names>WE</given-names></name>
<name><surname>Shanahan</surname><given-names>L</given-names></name>
<name><surname>Costello</surname><given-names>EJ</given-names></name>
<name><surname>Angold</surname><given-names>A</given-names></name>
</person-group> (<year>2009</year>) <article-title>Childhood and adolescent psychiatric disorders as predictors of young adult disorders</article-title>. <source>Arch Gen Psychiatry</source> <volume>66</volume>: <fpage>764</fpage>–<lpage>772</lpage>.</citation>
</ref>
<ref id="bibr30-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Coplan</surname><given-names>JD</given-names></name>
<name><surname>Moreau</surname><given-names>D</given-names></name>
<name><surname>Chaput</surname><given-names>F</given-names></name>
<etal/>
</person-group>. (<year>2002</year>) <article-title>Salivary cortisol concentrations before and after carbon-dioxide inhalations in children</article-title>. <source>Biol Psychiatry</source> <volume>51</volume>: <fpage>326</fpage>–<lpage>333</lpage>.</citation>
</ref>
<ref id="bibr31-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Davies</surname><given-names>SJ</given-names></name>
<name><surname>Hood</surname><given-names>SD</given-names></name>
<name><surname>Argyropoulos</surname><given-names>SV</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Depleting serotonin enhances both cardiovascular and psychological stress reactivity in recovered patients with anxiety disorders</article-title>. <source>J Clin Psychopharmacol</source> <volume>26</volume>: <fpage>414</fpage>–<lpage>418</lpage>.</citation>
</ref>
<ref id="bibr32-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dorn</surname><given-names>LD</given-names></name>
<name><surname>Campo</surname><given-names>JC</given-names></name>
<name><surname>Thato</surname><given-names>S</given-names></name>
<etal/>
</person-group>. (<year>2003</year>) <article-title>Psychological comorbidity and stress reactivity in children and adolescents with recurrent abdominal pain and anxiety disorders</article-title>. <source>J Am Acad Child Adolesc Psychiatry</source> <volume>42</volume>: <fpage>66</fpage>–<lpage>75</lpage>.</citation>
</ref>
<ref id="bibr33-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Essau</surname><given-names>CA</given-names></name>
<name><surname>Conradt</surname><given-names>J</given-names></name>
<name><surname>Petermann</surname><given-names>F</given-names></name>
</person-group> (<year>1999</year>) <article-title>Frequency of panic attacks and panic disorder in adolescents</article-title>. <source>Depress Anxiety</source> <volume>9</volume>: <fpage>19</fpage>–<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr34-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Feder</surname><given-names>A</given-names></name>
<name><surname>Coplan</surname><given-names>JD</given-names></name>
<name><surname>Goetz</surname><given-names>RR</given-names></name>
<etal/>
</person-group>. (<year>2004</year>) <article-title>Twenty-four-hour cortisol secretion patterns in prepubertal children with anxiety or depressive disorders</article-title>. <source>Biol Psychiatry</source> <volume>56</volume>: <fpage>198</fpage>–<lpage>204</lpage>.</citation>
</ref>
<ref id="bibr35-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fehm</surname><given-names>L</given-names></name>
<name><surname>Pelissolo</surname><given-names>A</given-names></name>
<name><surname>Furmark</surname><given-names>T</given-names></name>
<name><surname>Wittchen</surname><given-names>HU</given-names></name>
</person-group> (<year>2005</year>) <article-title>Size and burden of social phobia in Europe</article-title>. <source>Eur Neuropsychopharmacol</source> <volume>15</volume>: <fpage>453</fpage>–<lpage>462</lpage>.</citation>
</ref>
<ref id="bibr36-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ferdinand</surname><given-names>RF</given-names></name>
<name><surname>Dieleman</surname><given-names>G</given-names></name>
<name><surname>Ormel</surname><given-names>J</given-names></name>
<name><surname>Verhulst</surname><given-names>FC</given-names></name>
</person-group> (<year>2007</year>) <article-title>Homotypic versus heterotypic continuity of anxiety symptoms in young adolescents: evidence for distinctions between DSM-IV subtypes</article-title>. <source>J Abnorm Child Psychol</source> <volume>35</volume>: <fpage>325</fpage>–<lpage>333</lpage>.</citation>
</ref>
<ref id="bibr37-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Flannery-Schroeder</surname><given-names>EC</given-names></name>
</person-group> (<year>2006</year>) <article-title>Reducing anxiety to prevent depression</article-title>. <source>Am J Prevent Med</source> <volume>31</volume>(<issue>suppl 1</issue>): <fpage>136</fpage>–<lpage>142</lpage>.</citation>
</ref>
<ref id="bibr38-0269881110372818">
<citation citation-type="journal">
<collab>Food and Drug Administration</collab> (<year>2004</year>) <article-title>Worsening depression and suicidality in patients being treated with antidepressant</article-title>. <source>FDA Public Health Advisory</source>. <comment>FDA</comment>, <fpage>1</fpage>–<lpage>3</lpage>.</citation>
</ref>
<ref id="bibr39-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Forbes</surname><given-names>EE</given-names></name>
<name><surname>Williamson</surname><given-names>DE</given-names></name>
<name><surname>Ryan</surname><given-names>ND</given-names></name>
<name><surname>Birmaher</surname><given-names>B</given-names></name>
<name><surname>Axelson</surname><given-names>DA</given-names></name>
<name><surname>Dahl</surname><given-names>RE</given-names></name>
</person-group> (<year>2006</year>) <article-title>Peri-sleep-onset cortisol levels in children and adolescents with affective disorders</article-title>. <source>Biol Psychiatry</source> <volume>59</volume>: <fpage>24</fpage>–<lpage>30</lpage>.</citation>
</ref>
<ref id="bibr40-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ford</surname><given-names>T</given-names></name>
<name><surname>Goodman</surname><given-names>R</given-names></name>
<name><surname>Meltzer</surname><given-names>H</given-names></name>
</person-group> (<year>2003</year>) <article-title>The British Child and Adolescent Mental Health Survey 1999: the prevalence of DSM-IV disorders</article-title>. <source>J Am Acad Child Adolesc Psychiatry</source> <volume>42</volume>: <fpage>1203</fpage>–<lpage>1211</lpage>.</citation>
</ref>
<ref id="bibr41-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fyer</surname><given-names>MR</given-names></name>
<name><surname>Uy</surname><given-names>J</given-names></name>
<name><surname>Martinez</surname><given-names>J</given-names></name>
<etal/>
</person-group>. (<year>1987</year>) <article-title>CO<sub>2</sub> challenge of patients with panic disorder</article-title>. <source>Am J Psychiatry</source> <volume>144</volume>: <fpage>1080</fpage>–<lpage>1082</lpage>.</citation>
</ref>
<ref id="bibr42-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gerra</surname><given-names>G</given-names></name>
<name><surname>Volpi</surname><given-names>R</given-names></name>
<name><surname>Delsignore</surname><given-names>R</given-names></name>
<etal/>
</person-group>. (<year>1992</year>) <article-title>ACTH and beta-endorphin responses to physical exercise in adolescent women tested for anxiety and frustration</article-title>. <source>Psychiatry Res</source> <volume>41</volume>: <fpage>179</fpage>–<lpage>186</lpage>.</citation>
</ref>
<ref id="bibr43-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gerra</surname><given-names>G</given-names></name>
<name><surname>Zaimovic</surname><given-names>A</given-names></name>
<name><surname>Zambelli</surname><given-names>U</given-names></name>
<etal/>
</person-group>. (<year>2000</year>) <article-title>Neuroendocrine responses to psychological stress in adolescents with anxiety disorder</article-title>. <source>Neuropsychobiology</source> <volume>42</volume>: <fpage>82</fpage>–<lpage>92</lpage>.</citation>
</ref>
<ref id="bibr44-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goldstein</surname><given-names>S</given-names></name>
<name><surname>Halbreich</surname><given-names>U</given-names></name>
<name><surname>Asnis</surname><given-names>G</given-names></name>
<name><surname>Endicott</surname><given-names>J</given-names></name>
<name><surname>Alvir</surname><given-names>J</given-names></name>
</person-group> (<year>1987</year>) <article-title>The hypothalamic-pituitary-adrenal system in panic disorder</article-title>. <source>Am J Psychiatry</source> <volume>144</volume>: <fpage>1320</fpage>–<lpage>1323</lpage>.</citation>
</ref>
<ref id="bibr45-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gorman</surname><given-names>JM</given-names></name>
</person-group> (<year>1996</year>) <article-title>Comorbid depression and anxiety spectrum disorders</article-title>. <source>Depress Anxiety</source> <volume>4</volume>: <fpage>160</fpage>–<lpage>168</lpage>.</citation>
</ref>
<ref id="bibr46-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gorman</surname><given-names>JM</given-names></name>
<name><surname>Fyer</surname><given-names>MR</given-names></name>
<name><surname>Goetz</surname><given-names>R</given-names></name>
<etal/>
</person-group>. (<year>1988</year>) <article-title>Ventilatory physiology of patients with panic disorder</article-title>. <source>Arch Gen Psychiatry</source> <volume>45</volume>: <fpage>31</fpage>–<lpage>39</lpage>.</citation>
</ref>
<ref id="bibr47-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gorman</surname><given-names>JM</given-names></name>
<name><surname>Papp</surname><given-names>LA</given-names></name>
<name><surname>Martinez</surname><given-names>J</given-names></name>
<etal/>
</person-group>. (<year>1990</year>) <article-title>High-dose carbon dioxide challenge test in anxiety disorder patients</article-title>. <source>Biol Psychiatry</source> <volume>28</volume>: <fpage>743</fpage>–<lpage>757</lpage>.</citation>
</ref>
<ref id="bibr48-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Granger</surname><given-names>DA</given-names></name>
<name><surname>Weisz</surname><given-names>JR</given-names></name>
<name><surname>Kauneckis</surname><given-names>D</given-names></name>
</person-group> (<year>1994</year>) <article-title>Neuroendocrine reactivity, internalizing behavior problems, and control-repeated cognitions in clinic-referred children and adolescents</article-title>. <source>J Abnormal Psychol</source> <volume>103</volume>: <fpage>267</fpage>–<lpage>276</lpage>.</citation>
</ref>
<ref id="bibr49-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Greaves-Lord</surname><given-names>K</given-names></name>
<name><surname>Ferdinand</surname><given-names>RF</given-names></name>
<name><surname>Oldehinkel</surname><given-names>AJ</given-names></name>
<name><surname>Sondeijker</surname><given-names>FE</given-names></name>
<name><surname>Ormel</surname><given-names>J</given-names></name>
<name><surname>Verhulst</surname><given-names>FC</given-names></name>
</person-group> (<year>2007</year>) <article-title>Higher cortisol awakening response in young adolescents with persistent anxiety problems</article-title>. <source>Acta Psychiatr Scand</source> <volume>116</volume>: <fpage>137</fpage>–<lpage>144</lpage>.</citation>
</ref>
<ref id="bibr50-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gregory</surname><given-names>AM</given-names></name>
<name><surname>Caspi</surname><given-names>A</given-names></name>
<name><surname>Moffitt</surname><given-names>TE</given-names></name>
<name><surname>Koenen</surname><given-names>K</given-names></name>
<name><surname>Eley</surname><given-names>TC</given-names></name>
<name><surname>Poulton</surname><given-names>R</given-names></name>
</person-group> (<year>2007</year>) <article-title>Juvenile mental health histories of adults with anxiety disorders</article-title>. <source>Am J Psychiatry</source> <volume>164</volume>: <fpage>301</fpage>–<lpage>308</lpage>.</citation>
</ref>
<ref id="bibr51-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Griez</surname><given-names>E</given-names></name>
<name><surname>Schruers</surname><given-names>K</given-names></name>
</person-group> (<year>1998</year>) <article-title>Experimental pathophysiology of panic</article-title>. <source>J Psychosom Res</source> <volume>45</volume>: <fpage>493</fpage>–<lpage>503</lpage>.</citation>
</ref>
<ref id="bibr52-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Griez</surname><given-names>E</given-names></name>
<name><surname>Zandbergen</surname><given-names>J</given-names></name>
<name><surname>Pols</surname><given-names>H</given-names></name>
<name><surname>de Loof</surname><given-names>C</given-names></name>
</person-group> (<year>1990</year>) <article-title>Response to 35% CO<sub>2</sub> as a marker of panic in severe anxiety</article-title>. <source>Am J Psychiatry</source> <volume>147</volume>: <fpage>796</fpage>–<lpage>797</lpage>.</citation>
</ref>
<ref id="bibr53-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gurguis</surname><given-names>GN</given-names></name>
<name><surname>Uhde</surname><given-names>TW</given-names></name>
</person-group> (<year>1990</year>) <article-title>Plasma 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) and growth hormone responses to yohimbine in panic disorder patients and normal controls</article-title>. <source>Psychoneuroendocrinology</source> <volume>15</volume>: <fpage>217</fpage>–<lpage>224</lpage>.</citation>
</ref>
<ref id="bibr54-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gurguis</surname><given-names>GN</given-names></name>
<name><surname>Vitton</surname><given-names>BJ</given-names></name>
<name><surname>Uhde</surname><given-names>TW</given-names></name>
</person-group> (<year>1997</year>) <article-title>Behavioral, sympathetic and adrenocortical responses to yohimbine in panic disorder patients and normal controls</article-title>. <source>Psychiatry Res</source> <volume>71</volume>: <fpage>27</fpage>–<lpage>39</lpage>.</citation>
</ref>
<ref id="bibr55-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Halperin</surname><given-names>JM</given-names></name>
<name><surname>Newcorn</surname><given-names>JH</given-names></name>
<name><surname>Kopstein</surname><given-names>I</given-names></name>
<etal/>
</person-group>. (<year>1997</year>) <article-title>Serotonin, aggression, and parental psychopathology in children with attention-deficit hyperactivity disorder</article-title>. <source>J Am Acad Child Adolesc Psychiatry</source> <volume>36</volume>: <fpage>1391</fpage>–<lpage>1398</lpage>.</citation>
</ref>
<ref id="bibr56-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Halperin</surname><given-names>JM</given-names></name>
<name><surname>Sharma</surname><given-names>V</given-names></name>
<name><surname>Siever</surname><given-names>LJ</given-names></name>
<etal/>
</person-group>. (<year>1994</year>) <article-title>Serotonergic function in aggressive and nonaggressive boys with attention deficit hyperactivity disorder</article-title>. <source>Am J Psychiatry</source> <volume>151</volume>: <fpage>243</fpage>–<lpage>248</lpage>.</citation>
</ref>
<ref id="bibr57-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hayward</surname><given-names>C</given-names></name>
<name><surname>Wilson</surname><given-names>KA</given-names></name>
<name><surname>Lagle</surname><given-names>K</given-names></name>
<name><surname>Kraemer</surname><given-names>HC</given-names></name>
<name><surname>Killen</surname><given-names>JD</given-names></name>
<name><surname>Taylor</surname><given-names>CB</given-names></name>
</person-group> (<year>2008</year>) <article-title>The developmental psychopathology of social anxiety in adolescents</article-title>. <source>Depress Anxiety</source> <volume>25</volume>: <fpage>200</fpage>–<lpage>206</lpage>.</citation>
</ref>
<ref id="bibr58-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hollander</surname><given-names>E</given-names></name>
<name><surname>Kwon</surname><given-names>J</given-names></name>
<name><surname>Weiller</surname><given-names>F</given-names></name>
<etal/>
</person-group>. (<year>1998</year>) <article-title>Serotonergic function in social phobia: comparison to normal control and obsessive-compulsive disorder subjects</article-title>. <source>Psychiatry Res</source> <volume>79</volume>: <fpage>213</fpage>–<lpage>217</lpage>.</citation>
</ref>
<ref id="bibr59-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Holsboer</surname><given-names>F</given-names></name>
<name><surname>von Bardeleben</surname><given-names>U</given-names></name>
<name><surname>Buller</surname><given-names>R</given-names></name>
<name><surname>Heuser</surname><given-names>I</given-names></name>
<name><surname>Steiger</surname><given-names>A</given-names></name>
</person-group> (<year>1987</year>) <article-title>Stimulation response to corticotropin-releasing hormone (CRH) in patients with depression, alcoholism and panic disorder</article-title>. <source>Horm Metab Res</source> <volume>16</volume>(<issue>suppl</issue>): <fpage>80</fpage>–<lpage>88</lpage>.</citation>
</ref>
<ref id="bibr60-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hood</surname><given-names>SD</given-names></name>
<name><surname>Bell</surname><given-names>CJ</given-names></name>
<name><surname>Nutt</surname><given-names>DJ</given-names></name>
</person-group> (<year>2005</year>) <article-title>Acute tryptophan depletion. Part I: rationale and methodology</article-title>. <source>Aust N Z J Psychiatry</source> <volume>39</volume>: <fpage>558</fpage>–<lpage>564</lpage>.</citation>
</ref>
<ref id="bibr61-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jensen</surname><given-names>JB</given-names></name>
<name><surname>Garfinkel</surname><given-names>BD</given-names></name>
</person-group> (<year>1990</year>) <article-title>Growth hormone dysregulation in children with major depressive disorder</article-title>. <source>J Am Acad Child Adolesc Psychiatry</source> <volume>29</volume>: <fpage>295</fpage>–<lpage>301</lpage>.</citation>
</ref>
<ref id="bibr62-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kagan</surname><given-names>J</given-names></name>
<name><surname>Reznick</surname><given-names>JS</given-names></name>
<name><surname>Snidman</surname><given-names>N</given-names></name>
</person-group> (<year>1988</year>) <article-title>Biological bases of childhood shyness</article-title>. <source>Science</source> <volume>240</volume>: <fpage>167</fpage>–<lpage>171</lpage>.</citation>
</ref>
<ref id="bibr63-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kallen</surname><given-names>VL</given-names></name>
<name><surname>Tulen</surname><given-names>JH</given-names></name>
<name><surname>Utens</surname><given-names>EM</given-names></name>
<name><surname>Treffers</surname><given-names>PD</given-names></name>
<name><surname>De Jong</surname><given-names>FH</given-names></name>
<name><surname>Ferdinand</surname><given-names>RF</given-names></name>
</person-group> (<year>2008</year>) <article-title>Associations between HPA axis functioning and level of anxiety in children and adolescents with an anxiety disorder</article-title>. <source>Depress Anxiety</source> <volume>25</volume>: <fpage>131</fpage>–<lpage>141</lpage>.</citation>
</ref>
<ref id="bibr64-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kathol</surname><given-names>RG</given-names></name>
<name><surname>Noyes</surname><given-names>R</given-names></name>
<name><surname>Lopez</surname><given-names>A</given-names></name>
</person-group> (<year>1988</year>) <article-title>Similarities in hypothalamic-pituitary-adrenal axis activity between patients with panic disorder and those experiencing external stress</article-title>. <source>Psychiatr Clin North Am</source> <volume>11</volume>: <fpage>335</fpage>–<lpage>348</lpage>.</citation>
</ref>
<ref id="bibr65-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Katzman</surname><given-names>MA</given-names></name>
<name><surname>Koszycki</surname><given-names>D</given-names></name>
<name><surname>Bradwejn</surname><given-names>J</given-names></name>
</person-group> (<year>2004</year>) <article-title>Effects of CCK-tetrapeptide in patients with social phobia and obsessive-compulsive disorder</article-title>. <source>Depress Anxiety</source> <volume>20</volume>: <fpage>51</fpage>–<lpage>58</lpage>.</citation>
</ref>
<ref id="bibr66-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kessler</surname><given-names>RC</given-names></name>
<name><surname>Berglund</surname><given-names>P</given-names></name>
<name><surname>Demler</surname><given-names>O</given-names></name>
<name><surname>Jin</surname><given-names>R</given-names></name>
<name><surname>Merikangas</surname><given-names>KR</given-names></name>
<name><surname>Walters</surname><given-names>EE</given-names></name>
</person-group> (<year>2005a</year>) <article-title>Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication</article-title>. <source>Arch Gen Psychiatry</source> <volume>62</volume>: <fpage>593</fpage>–<lpage>602</lpage>.</citation>
</ref>
<ref id="bibr67-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kessler</surname><given-names>RC</given-names></name>
<name><surname>Chiu</surname><given-names>WT</given-names></name>
<name><surname>Demler</surname><given-names>O</given-names></name>
<name><surname>Merikangas</surname><given-names>KR</given-names></name>
<name><surname>Walters</surname><given-names>EE</given-names></name>
</person-group> (<year>2005b</year>) <article-title>Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication</article-title>. <source>Arch Gen Psychiatry</source> <volume>62</volume>: <fpage>617</fpage>–<lpage>627</lpage>.</citation>
</ref>
<ref id="bibr68-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kessler</surname><given-names>RC</given-names></name>
<name><surname>Chiu</surname><given-names>WT</given-names></name>
<name><surname>Jin</surname><given-names>R</given-names></name>
<name><surname>Ruscio</surname><given-names>AM</given-names></name>
<name><surname>Shear</surname><given-names>K</given-names></name>
<name><surname>Walters</surname><given-names>EE</given-names></name>
</person-group> (<year>2006</year>) <article-title>The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication</article-title>. <source>Arch Gen Psychiatry</source> <volume>63</volume>: <fpage>415</fpage>–<lpage>424</lpage>.</citation>
</ref>
<ref id="bibr69-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kessler</surname><given-names>RC</given-names></name>
<name><surname>McGonagle</surname><given-names>KA</given-names></name>
<name><surname>Zhao</surname><given-names>S</given-names></name>
<etal/>
</person-group>. (<year>1994</year>) <article-title>Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey</article-title>. <source>Arch Gen Psychiatry</source> <volume>51</volume>: <fpage>8</fpage>–<lpage>19</lpage>.</citation>
</ref>
<ref id="bibr70-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim-Cohen</surname><given-names>J</given-names></name>
<name><surname>Caspi</surname><given-names>A</given-names></name>
<name><surname>Moffitt</surname><given-names>TE</given-names></name>
<name><surname>Harrington</surname><given-names>H</given-names></name>
<name><surname>Milne</surname><given-names>BJ</given-names></name>
<name><surname>Poulton</surname><given-names>R</given-names></name>
</person-group> (<year>2003</year>) <article-title>Prior juvenile diagnoses in adults with mental disorder: developmental follow-back of a prospective-longitudinal cohort</article-title>. <source>Arch Gen Psychiatry</source> <volume>60</volume>: <fpage>709</fpage>–<lpage>717</lpage>.</citation>
</ref>
<ref id="bibr71-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Klein</surname><given-names>DF</given-names></name>
</person-group> (<year>1994</year>) <article-title>Testing the suffocation false alarm theory of panic disorder</article-title>. <source>Anxiety</source> <volume>1</volume>: <fpage>1</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr72-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Krueger</surname><given-names>RF</given-names></name>
</person-group> (<year>1999</year>) <article-title>The structure of common mental disorders</article-title>. <source>Arch Gen Psychiatry</source> <volume>56</volume>: <fpage>921</fpage>–<lpage>926</lpage>.</citation>
</ref>
<ref id="bibr73-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Krystal</surname><given-names>JH</given-names></name>
<name><surname>Deutsch</surname><given-names>DN</given-names></name>
<name><surname>Charney</surname><given-names>DS</given-names></name>
</person-group> (<year>1996</year>) <article-title>The biological basis of panic disorder</article-title>. <source>J Clin Psychiatry</source> <volume>57</volume>(<issue>suppl 10</issue>): <fpage>23</fpage>–<lpage>33</lpage>.</citation>
</ref>
<ref id="bibr74-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lépine</surname><given-names>JP</given-names></name>
</person-group> (<year>2001</year>) <article-title>Epidemiology, burden, and disability in depression and anxiety</article-title>. <source>J Clin Psychiatry</source> <volume>62</volume>(<issue>suppl 13</issue>): <fpage>4</fpage>–<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr75-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lépine</surname><given-names>JP</given-names></name>
</person-group> (<year>2002</year>) <article-title>The epidemiology of anxiety disorders: prevalence and societal costs</article-title>. <source>J Clin Psychiatry</source> <volume>63</volume>(<issue>suppl 14</issue>): <fpage>4</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr76-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lépine</surname><given-names>JP</given-names></name>
<name><surname>Lellouch</surname><given-names>J</given-names></name>
</person-group> (<year>1995</year>) <article-title>Classification and epidemiology of social phobia</article-title>. <source>Eur Arch Psychiatry Clin Neurosci</source> <volume>244</volume>: <fpage>290</fpage>–<lpage>296</lpage>.</citation>
</ref>
<ref id="bibr77-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lewinsohn</surname><given-names>PM</given-names></name>
<name><surname>Hops</surname><given-names>H</given-names></name>
<name><surname>Roberts</surname><given-names>RE</given-names></name>
<name><surname>Seeley</surname><given-names>JR</given-names></name>
<name><surname>Andrews</surname><given-names>JA</given-names></name>
</person-group> (<year>1993</year>) <article-title>Adolescent psychopathology: I. Prevalence and incidence of depression and other DSM-III-R disorders in high school students</article-title>. <source>J Abnorm Psychol</source> <volume>102</volume>: <fpage>133</fpage>–<lpage>144</lpage>.</citation>
</ref>
<ref id="bibr78-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Liebowitz</surname><given-names>MR</given-names></name>
<name><surname>Fyer</surname><given-names>AJ</given-names></name>
<name><surname>Gorman</surname><given-names>JM</given-names></name>
<etal/>
</person-group>. (<year>1984</year>) <article-title>Lactate provocation of panic attacks. I. Clinical and behavioral findings</article-title>. <source>Arch Gen Psychiatry</source> <volume>41</volume>: <fpage>764</fpage>–<lpage>770</lpage>.</citation>
</ref>
<ref id="bibr79-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Liebowitz</surname><given-names>MR</given-names></name>
<name><surname>Fyer</surname><given-names>AJ</given-names></name>
<name><surname>Gorman</surname><given-names>JM</given-names></name>
<etal/>
</person-group>. (<year>1985</year>) <article-title>Specificity of lactate infusions in social phobia versus panic disorders</article-title>. <source>Am J Psychiatry</source> <volume>142</volume>: <fpage>947</fpage>–<lpage>950</lpage>.</citation>
</ref>
<ref id="bibr80-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Livingston</surname><given-names>R</given-names></name>
<name><surname>Martin-Cannici</surname><given-names>C</given-names></name>
</person-group> (<year>1987</year>) <article-title>Depression, anxiety and the dexamethasone suppression test in hospitalized prepubertal children</article-title>. <source>Hillside J Clin Psychiatry</source> <volume>9</volume>: <fpage>55</fpage>–<lpage>63</lpage>.</citation>
</ref>
<ref id="bibr81-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Luboshitzky</surname><given-names>R</given-names></name>
</person-group> (<year>2000</year>) <article-title>Endocrine activity during sleep</article-title>. <source>J Pediatr Endocrinol Metab</source> <volume>13</volume>: <fpage>13</fpage>–<lpage>20</lpage>.</citation>
</ref>
<ref id="bibr82-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Martel</surname><given-names>FL</given-names></name>
<name><surname>Hayward</surname><given-names>C</given-names></name>
<name><surname>Lyons</surname><given-names>DM</given-names></name>
<name><surname>Sanborn</surname><given-names>K</given-names></name>
<name><surname>Varady</surname><given-names>S</given-names></name>
<name><surname>Schatzberg</surname><given-names>AF</given-names></name>
</person-group> (<year>1999</year>) <article-title>Salivary cortisol levels in socially phobic adolescent girls</article-title>. <source>Depress Anxiety</source> <volume>10</volume>: <fpage>25</fpage>–<lpage>27</lpage>.</citation>
</ref>
<ref id="bibr83-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Maughan</surname><given-names>B</given-names></name>
<name><surname>Kim-Cohen</surname><given-names>J</given-names></name>
</person-group> (<year>2005</year>) <article-title>Continuities between childhood and adult life</article-title>. <source>Br J Psychiatry</source> <volume>187</volume>: <fpage>301</fpage>–<lpage>303</lpage>.</citation>
</ref>
<ref id="bibr84-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McCann</surname><given-names>UD</given-names></name>
<name><surname>Slate</surname><given-names>SO</given-names></name>
<name><surname>Geraci</surname><given-names>M</given-names></name>
<name><surname>Roscow-Terrill</surname><given-names>D</given-names></name>
<name><surname>Uhde</surname><given-names>TW</given-names></name>
</person-group> (<year>1997</year>) <article-title>A comparison of the effects of intravenous pentagastrin on patients with social phobia, panic disorder and healthy controls</article-title>. <source>Neuropsychopharmacology</source> <volume>16</volume>: <fpage>229</fpage>–<lpage>237</lpage>.</citation>
</ref>
<ref id="bibr85-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Monk</surname><given-names>C</given-names></name>
<name><surname>Kovelenko</surname><given-names>P</given-names></name>
<name><surname>Ellman</surname><given-names>LM</given-names></name>
<etal/>
</person-group>. (<year>2001</year>) <article-title>Enhanced stress reactivity in paediatric anxiety disorders: implications for future cardiovascular health</article-title>. <source>Int J Neuropsychopharmacol</source> <volume>4</volume>: <fpage>199</fpage>–<lpage>206</lpage>.</citation>
</ref>
<ref id="bibr86-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nardi</surname><given-names>AE</given-names></name>
<name><surname>Lopes</surname><given-names>FL</given-names></name>
<name><surname>Freire</surname><given-names>RC</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>Panic disorder and social anxiety disorder subtypes in a caffeine challenge test</article-title>. <source>Psychiatry Res</source> <volume>169</volume>: <fpage>149</fpage>–<lpage>153</lpage>.</citation>
</ref>
<ref id="bibr87-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nardi</surname><given-names>AE</given-names></name>
<name><surname>Lopes</surname><given-names>FL</given-names></name>
<name><surname>Valença</surname><given-names>AM</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Caffeine challenge test in panic disorder and depression with panic attacks</article-title>. <source>Compr Psychiatry</source> <volume>48</volume>: <fpage>257</fpage>–<lpage>263</lpage>.</citation>
</ref>
<ref id="bibr88-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nutt</surname><given-names>DJ</given-names></name>
</person-group> (<year>1989</year>) <article-title>Altered central alpha 2-adrenoceptor sensitivity in panic disorder</article-title>. <source>Arch Gen Psychiatry</source> <volume>46</volume>: <fpage>165</fpage>–<lpage>169</lpage>.</citation>
</ref>
<ref id="bibr89-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nutt</surname><given-names>DJ</given-names></name>
<name><surname>Bell</surname><given-names>CJ</given-names></name>
<name><surname>Malizia</surname><given-names>AL</given-names></name>
</person-group> (<year>1998</year>) <article-title>Brain mechanisms of social anxiety disorder</article-title>. <source>J Clin Psychiatry</source> <volume>59</volume>(<issue>suppl 17</issue>): <fpage>4</fpage>–<lpage>11</lpage>.</citation>
</ref>
<ref id="bibr90-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Papp</surname><given-names>LA</given-names></name>
<name><surname>Klein</surname><given-names>DF</given-names></name>
<name><surname>Martinez</surname><given-names>J</given-names></name>
<etal/>
</person-group>. (<year>1993</year>) <article-title>Diagnostic and substance specificity of carbon-dioxide-induced panic</article-title>. <source>Am J Psychiatry</source> <volume>150</volume>: <fpage>250</fpage>–<lpage>257</lpage>.</citation>
</ref>
<ref id="bibr91-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Perna</surname><given-names>G</given-names></name>
<name><surname>Barbini</surname><given-names>B</given-names></name>
<name><surname>Cocchi</surname><given-names>S</given-names></name>
<name><surname>Bertani</surname><given-names>A</given-names></name>
<name><surname>Gasperini</surname><given-names>M</given-names></name>
</person-group> (<year>1995</year>) <article-title>35% CO<sub>2</sub> challenge in panic and mood disorders</article-title>. <source>J Affect Disord</source> <volume>33</volume>: <fpage>189</fpage>–<lpage>194</lpage>.</citation>
</ref>
<ref id="bibr92-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pick</surname><given-names>LH</given-names></name>
<name><surname>Halperin</surname><given-names>JM</given-names></name>
<name><surname>Schwartz</surname><given-names>ST</given-names></name>
<name><surname>Newcorn</surname><given-names>JH</given-names></name>
</person-group> (<year>1999</year>) <article-title>A longitudinal study of neurobiological mechanisms in boys with attention-deficit hyperactivity disorder: preliminary findings</article-title>. <source>Biol Psychiatry</source> <volume>45</volume>: <fpage>371</fpage>–<lpage>373</lpage>.</citation>
</ref>
<ref id="bibr93-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pine</surname><given-names>DS</given-names></name>
</person-group> (<year>1999</year>) <article-title>Pathophysiology of childhood anxiety disorders</article-title>. <source>Biol Psychiatry</source> <volume>46</volume>: <fpage>1555</fpage>–<lpage>1566</lpage>.</citation>
</ref>
<ref id="bibr94-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pine</surname><given-names>DS</given-names></name>
</person-group> (<year>2002</year>) <article-title>Treating children and adolescents with selective serotonin reuptake inhibitors: how long is appropriate?</article-title>. <source>J Child Adolesc Psychopharmacol</source> <volume>12</volume>: <fpage>189</fpage>–<lpage>203</lpage>.</citation>
</ref>
<ref id="bibr95-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pine</surname><given-names>DS</given-names></name>
<name><surname>Cohen</surname><given-names>P</given-names></name>
<name><surname>Gurley</surname><given-names>D</given-names></name>
<name><surname>Brook</surname><given-names>J</given-names></name>
<name><surname>Ma</surname><given-names>Y</given-names></name>
</person-group> (<year>1998a</year>) <article-title>The risk for early-adulthood anxiety and depressive disorders in adolescents with anxiety and depressive disorders</article-title>. <source>Arch Gen Psychiatry</source> <volume>55</volume>: <fpage>56</fpage>–<lpage>64</lpage>.</citation>
</ref>
<ref id="bibr96-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pine</surname><given-names>DS</given-names></name>
<name><surname>Coplan</surname><given-names>JD</given-names></name>
<name><surname>Papp</surname><given-names>LA</given-names></name>
<etal/>
</person-group>. (<year>1998b</year>) <article-title>Ventilatory physiology of children and adolescents with anxiety disorders</article-title>. <source>Arch Gen Psychiatry</source> <volume>55</volume>: <fpage>123</fpage>–<lpage>129</lpage>.</citation>
</ref>
<ref id="bibr97-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pine</surname><given-names>DS</given-names></name>
<name><surname>Klein</surname><given-names>RG</given-names></name>
<name><surname>Coplan</surname><given-names>JD</given-names></name>
<etal/>
</person-group>. (<year>2000</year>) <article-title>Differential carbon dioxide sensitivity in childhood anxiety disorders and nonill comparison group</article-title>. <source>Arch Gen Psychiatry</source> <volume>57</volume>: <fpage>960</fpage>–<lpage>967</lpage>.</citation>
</ref>
<ref id="bibr98-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pine</surname><given-names>DS</given-names></name>
<name><surname>Klein</surname><given-names>RG</given-names></name>
<name><surname>Roberson-Nay</surname><given-names>R</given-names></name>
<etal/>
</person-group>. (<year>2005</year>) <article-title>Response to 5% carbon dioxide in children and adolescents: relationship to panic disorder in parents and anxiety disorders in subjects</article-title>. <source>Arch Gen Psychiatry</source> <volume>62</volume>: <fpage>73</fpage>–<lpage>80</lpage>.</citation>
</ref>
<ref id="bibr99-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pine</surname><given-names>DS</given-names></name>
<name><surname>Weese-Mayer</surname><given-names>DE</given-names></name>
<name><surname>Silvestri</surname><given-names>JM</given-names></name>
<name><surname>Davies</surname><given-names>M</given-names></name>
<name><surname>Whitaker</surname><given-names>AH</given-names></name>
<name><surname>Klein</surname><given-names>DF</given-names></name>
</person-group> (<year>1994</year>) <article-title>Anxiety and congenital central hypoventilation syndrome</article-title>. <source>Am J Psychiatry</source> <volume>151</volume>: <fpage>864</fpage>–<lpage>870</lpage>.</citation>
</ref>
<ref id="bibr100-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Potts</surname><given-names>NL</given-names></name>
<name><surname>Book</surname><given-names>S</given-names></name>
<name><surname>Davidson</surname><given-names>JR</given-names></name>
</person-group> (<year>1996</year>) <article-title>The neurobiology of social phobia</article-title>. <source>Int Clin Psychopharmacol</source> <volume>11</volume>(<issue>suppl 3</issue>): <fpage>43</fpage>–<lpage>48</lpage>.</citation>
</ref>
<ref id="bibr101-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Puig-Antich</surname><given-names>J</given-names></name>
<name><surname>Tabrizi</surname><given-names>MA</given-names></name>
<name><surname>Davies</surname><given-names>M</given-names></name>
<etal/>
</person-group>. (<year>1981</year>) <article-title>Prepubertal endogenous major depressives hyposecrete growth hormone in response to insulin-induced hypoglycemia</article-title>. <source>Biol Psychiatry</source> <volume>16</volume>: <fpage>801</fpage>–<lpage>818</lpage>.</citation>
</ref>
<ref id="bibr102-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reed</surname><given-names>V</given-names></name>
<name><surname>Wittchen</surname><given-names>HU</given-names></name>
</person-group> (<year>1998</year>) <article-title>DSM-IV panic attacks and panic disorder in a community sample of adolescents and young adults: how specific are panic attacks?</article-title>. <source>J Psychiatr Res</source> <volume>32</volume>: <fpage>335</fpage>–<lpage>345</lpage>.</citation>
</ref>
<ref id="bibr103-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rutter</surname><given-names>M</given-names></name>
<name><surname>Kim-Cohen</surname><given-names>J</given-names></name>
<name><surname>Maughan</surname><given-names>B</given-names></name>
</person-group> (<year>2006</year>) <article-title>Continuities and discontinuities in psychopathology between childhood and adult life</article-title>. <source>J Child Psychol Psychiatry</source> <volume>47</volume>: <fpage>276</fpage>–<lpage>295</lpage>.</citation>
</ref>
<ref id="bibr104-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rowland</surname><given-names>NE</given-names></name>
<name><surname>Carlton</surname><given-names>J</given-names></name>
</person-group> (<year>1986</year>) <article-title>Neurobiology of an anorectic drug: fenfluramine</article-title>. <source>Prog Neurobiol</source> <volume>27</volume>: <fpage>13</fpage>–<lpage>62</lpage>.</citation>
</ref>
<ref id="bibr105-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Roy-Byrne</surname><given-names>PP</given-names></name>
<name><surname>Uhde</surname><given-names>TW</given-names></name>
<name><surname>Post</surname><given-names>RM</given-names></name>
<name><surname>Gallucci</surname><given-names>W</given-names></name>
<name><surname>Chrousos</surname><given-names>GP</given-names></name>
<name><surname>Gold</surname><given-names>PW</given-names></name>
</person-group> (<year>1986</year>) <article-title>The corticotropin-releasing hormone stimulation test in patients with panic disorder</article-title>. <source>Am J Psychiatry</source> <volume>143</volume>: <fpage>896</fpage>–<lpage>899</lpage>.</citation>
</ref>
<ref id="bibr106-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ryan</surname><given-names>ND</given-names></name>
<name><surname>Dahl</surname><given-names>RE</given-names></name>
<name><surname>Birmaher</surname><given-names>B</given-names></name>
<etal/>
</person-group>. (<year>1994</year>) <article-title>Stimulatory tests of growth hormone secretion in prepubertal major depression: depressed versus normal children</article-title>. <source>J Am Acad Child Adolesc Psychiatry</source> <volume>33</volume>: <fpage>824</fpage>–<lpage>833</lpage>.</citation>
</ref>
<ref id="bibr107-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sallee</surname><given-names>FR</given-names></name>
<name><surname>Richman</surname><given-names>H</given-names></name>
<name><surname>Sethuraman</surname><given-names>G</given-names></name>
<name><surname>Dougherty</surname><given-names>D</given-names></name>
<name><surname>Sine</surname><given-names>L</given-names></name>
<name><surname>Altman-Hamamdzic</surname><given-names>S</given-names></name>
</person-group> (<year>1998</year>) <article-title>Clonidine challenge in childhood anxiety disorder</article-title>. <source>J Am Acad Child Adolesc Psychiatry</source> <volume>37</volume>: <fpage>655</fpage>–<lpage>662</lpage>.</citation>
</ref>
<ref id="bibr108-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sallee</surname><given-names>FR</given-names></name>
<name><surname>Sethuraman</surname><given-names>G</given-names></name>
<name><surname>Sine</surname><given-names>L</given-names></name>
<name><surname>Liu</surname><given-names>H</given-names></name>
</person-group> (<year>2000b</year>) <article-title>Yohimbine challenge in children with anxiety disorders</article-title>. <source>Am J Psychiatry</source> <volume>157</volume>: <fpage>1236</fpage>–<lpage>1242</lpage>.</citation>
</ref>
<ref id="bibr109-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sallee</surname><given-names>FR</given-names></name>
<name><surname>Vrindavanam</surname><given-names>NS</given-names></name>
<name><surname>Liu</surname><given-names>H</given-names></name>
<name><surname>Sethuraman</surname><given-names>G</given-names></name>
<name><surname>Sine</surname><given-names>L</given-names></name>
</person-group> (<year>2000a</year>) <article-title>Fenfluramine challenge in anxious children</article-title>. <source>Hum Psychopharmacol</source> <volume>15</volume>: <fpage>619</fpage>–<lpage>629</lpage>.</citation>
</ref>
<ref id="bibr110-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sinha</surname><given-names>SS</given-names></name>
<name><surname>Coplan</surname><given-names>JD</given-names></name>
<name><surname>Pine</surname><given-names>DS</given-names></name>
<name><surname>Martinez</surname><given-names>JA</given-names></name>
<name><surname>Klein</surname><given-names>DF</given-names></name>
<name><surname>Gorman</surname><given-names>JM</given-names></name>
</person-group> (<year>1999</year>) <article-title>Panic induced by carbon dioxide inhalation and lack of hypothalamic-pituitary-adrenal axis activation</article-title>. <source>Psychiatry Res</source> <volume>86</volume>: <fpage>93</fpage>–<lpage>98</lpage>.</citation>
</ref>
<ref id="bibr111-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Slade</surname><given-names>T</given-names></name>
<name><surname>Watson</surname><given-names>D</given-names></name>
</person-group> (<year>2006</year>) <article-title>The structure of common DSM-IV and ICD-10 mental disorders in the Australian general population</article-title>. <source>Psychol Med</source> <volume>36</volume>: <fpage>1593</fpage>–<lpage>1600</lpage>.</citation>
</ref>
<ref id="bibr112-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stein</surname><given-names>MB</given-names></name>
<name><surname>Asmundson</surname><given-names>GJG</given-names></name>
<name><surname>Chartier</surname><given-names>M</given-names></name>
</person-group> (<year>1994</year>) <article-title>Autonomic responsivity in generalized social phobia</article-title>. <source>J Affect Disord</source> <volume>31</volume>: <fpage>211</fpage>–<lpage>221</lpage>.</citation>
</ref>
<ref id="bibr113-0269881110372818">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Stein</surname><given-names>MB</given-names></name>
<name><surname>de Boer</surname><given-names>JA</given-names></name>
</person-group> (<year>1999</year>) <article-title>The biological basis of social anxiety disorder</article-title>. In: <person-group person-group-type="editor">
<name><surname>Westenberg</surname><given-names>HGM</given-names></name>
</person-group> (ed.) <source>Focus on Psychiatry: Volume 2: Social Anxiety Disorder</source>. <publisher-loc>Amsterdam</publisher-loc>, <publisher-name>The Netherlands: Synthesis Publishers</publisher-name>, <comment>Ch 4</comment>, pp. <fpage>81</fpage>–<lpage>108</lpage>.</citation>
</ref>
<ref id="bibr114-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stein</surname><given-names>MB</given-names></name>
<name><surname>Fuetsch</surname><given-names>M</given-names></name>
<name><surname>Muller</surname><given-names>N</given-names></name>
<name><surname>Hofler</surname><given-names>M</given-names></name>
<name><surname>Lieb</surname><given-names>R</given-names></name>
<name><surname>Wittchen</surname><given-names>HU</given-names></name>
</person-group> (<year>2001</year>) <article-title>Social anxiety disorder and the risk of depression: a prospective community study of adolescents and young adults</article-title>. <source>Arch Gen Psychiatry</source> <volume>58</volume>: <fpage>251</fpage>–<lpage>256</lpage>.</citation>
</ref>
<ref id="bibr115-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stein</surname><given-names>MB</given-names></name>
<name><surname>Tancer</surname><given-names>ME</given-names></name>
<name><surname>Uhde</surname><given-names>TW</given-names></name>
</person-group> (<year>1992</year>) <article-title>Heart rate and plasma norepinephrine responsivity to orthostatic challenge in anxiety disorders. Comparison of patients with panic disorder and social phobia and normal control subjects</article-title>. <source>Arch Gen Psychiatry</source> <volume>49</volume>: <fpage>311</fpage>–<lpage>317</lpage>.</citation>
</ref>
<ref id="bibr116-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stoff</surname><given-names>DM</given-names></name>
<name><surname>Pasatiempo</surname><given-names>AP</given-names></name>
<name><surname>Yeung</surname><given-names>J</given-names></name>
<name><surname>Cooper</surname><given-names>TB</given-names></name>
<name><surname>Bridger</surname><given-names>WH</given-names></name>
<name><surname>Rabinovich</surname><given-names>H</given-names></name>
</person-group> (<year>1992</year>) <article-title>Neuroendocrine responses to challenge with dl-fenfluramine and aggression in disruptive behavior disorders of children and adolescents</article-title>. <source>Psychiatry Res</source> <volume>43</volume>: <fpage>263</fpage>–<lpage>276</lpage>.</citation>
</ref>
<ref id="bibr117-0269881110372818">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Swain</surname><given-names>J</given-names></name>
<name><surname>Koszycki</surname><given-names>D</given-names></name>
<name><surname>Shlik</surname><given-names>J</given-names></name>
<name><surname>Bradwejn</surname><given-names>J</given-names></name>
</person-group> (<year>2003</year>) <article-title>Pharmacological Challenge Agents in Anxiety</article-title>. In: <person-group person-group-type="editor">
<name><surname>Nutt</surname><given-names>DJ</given-names></name>
<name><surname>Ballenger</surname><given-names>J</given-names></name>
</person-group> (eds) <source>Anxiety Disorders</source>. <publisher-loc>Oxford</publisher-loc>: <publisher-name>Blackwell Publishing</publisher-name>, <comment>Ch 15</comment>, pp. <fpage>269</fpage>–<lpage>296</lpage>.</citation>
</ref>
<ref id="bibr118-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tancer</surname><given-names>ME</given-names></name>
</person-group> (<year>1993</year>) <article-title>Neurobiology of social phobia</article-title>. <source>J Clin Psychiatry</source> <volume>54</volume>(<issue>suppl</issue>): <fpage>26</fpage>–<lpage>30</lpage>.</citation>
</ref>
<ref id="bibr119-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tancer</surname><given-names>ME</given-names></name>
<name><surname>Mailman</surname><given-names>RB</given-names></name>
<name><surname>Stein</surname><given-names>MB</given-names></name>
<name><surname>Mason</surname><given-names>GA</given-names></name>
<name><surname>Carson</surname><given-names>SW</given-names></name>
<name><surname>Golden</surname><given-names>RN</given-names></name>
</person-group> (<year>1994</year>) <article-title>Neuroendocrine responsivity to monoaminergic system probes in generalized social phobia</article-title>. <source>Anxiety</source> <volume>1</volume>: <fpage>216</fpage>–<lpage>223</lpage>.</citation>
</ref>
<ref id="bibr120-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tancer</surname><given-names>ME</given-names></name>
<name><surname>Stein</surname><given-names>MB</given-names></name>
<name><surname>Black</surname><given-names>B</given-names></name>
<name><surname>Uhde</surname><given-names>TW</given-names></name>
</person-group> (<year>1993</year>) <article-title>Blunted growth hormone responses to growth hormone-releasing factor and to clonidine in panic disorder</article-title>. <source>Am J Psychiatry</source> <volume>150</volume>: <fpage>336</fpage>–<lpage>337</lpage>.</citation>
</ref>
<ref id="bibr121-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Targum</surname><given-names>SD</given-names></name>
<name><surname>Marshall</surname><given-names>LE</given-names></name>
</person-group> (<year>1989</year>) <article-title>Fenfluramine provocation of anxiety in patients with panic disorder</article-title>. <source>Psychiatry Res</source> <volume>28</volume>: <fpage>295</fpage>–<lpage>306</lpage>.</citation>
</ref>
<ref id="bibr122-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Terleph</surname><given-names>TA</given-names></name>
<name><surname>Klein</surname><given-names>RG</given-names></name>
<name><surname>Roberson-Nay</surname><given-names>R</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Stress responsivity and HPA axis activity in juveniles: results from a home-based CO<sub>2</sub> inhalation study</article-title>. <source>Am J Psychiatry</source> <volume>163</volume>: <fpage>738</fpage>–<lpage>740</lpage>.</citation>
</ref>
<ref id="bibr123-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Uhde</surname><given-names>TW</given-names></name>
<name><surname>Joffe</surname><given-names>RT</given-names></name>
<name><surname>Jimerson</surname><given-names>DC</given-names></name>
<name><surname>Post</surname><given-names>RM</given-names></name>
</person-group> (<year>1988</year>) <article-title>Normal urinary free cortisol and plasma MHPG in panic disorder: clinical and theoretical implications</article-title>. <source>Biol Psychiatry</source> <volume>23</volume>: <fpage>575</fpage>–<lpage>585</lpage>.</citation>
</ref>
<ref id="bibr124-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Uhde</surname><given-names>TW</given-names></name>
<name><surname>Tancer</surname><given-names>ME</given-names></name>
<name><surname>Gelernter</surname><given-names>CS</given-names></name>
<name><surname>Vittone</surname><given-names>BJ</given-names></name>
</person-group> (<year>1994</year>) <article-title>Normal urinary free cortisol and postdexamethasone cortisol in social phobia: comparison to normal volunteers</article-title>. <source>J Affect Disord</source> <volume>30</volume>: <fpage>155</fpage>–<lpage>161</lpage>.</citation>
</ref>
<ref id="bibr125-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Uhde</surname><given-names>TW</given-names></name>
<name><surname>Tancer</surname><given-names>ME</given-names></name>
<name><surname>Rubinow</surname><given-names>DR</given-names></name>
<etal/>
</person-group>. (<year>1992</year>) <article-title>Evidence for hypothalamo-growth hormone dysfunction in panic disorder: profile of growth hormone (GH) responses to clonidine, yohimbine, caffeine, glucose, GRF and TRH in panic disorder patients versus healthy volunteers</article-title>. <source>Neuropsychopharmacology</source> <comment>1992</comment> <volume>6</volume>: <fpage>101</fpage>–<lpage>118</lpage>.</citation>
</ref>
<ref id="bibr126-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Uhde</surname><given-names>TW</given-names></name>
<name><surname>Vittone</surname><given-names>BJ</given-names></name>
<name><surname>Siever</surname><given-names>LJ</given-names></name>
<name><surname>Kaye</surname><given-names>WH</given-names></name>
<name><surname>Post</surname><given-names>RM</given-names></name>
</person-group> (<year>1986</year>) <article-title>Blunted growth hormone response to clonidine in panic disorder patients</article-title>. <source>Biol Psychiatry</source> <volume>21</volume>: <fpage>1081</fpage>–<lpage>1085</lpage>.</citation>
</ref>
<ref id="bibr127-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Van den Hout</surname><given-names>MA</given-names></name>
<name><surname>Griez</surname><given-names>E</given-names></name>
</person-group> (<year>1982</year>) <article-title>Cardiovascular and subjective responses to inhalation of carbon dioxide. A controlled test with anxious patients</article-title>. <source>Psychother Psychosom</source> <volume>37</volume>: <fpage>75</fpage>–<lpage>82</lpage>.</citation>
</ref>
<ref id="bibr128-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Van den Hout</surname><given-names>MA</given-names></name>
<name><surname>Griez</surname><given-names>E</given-names></name>
</person-group> (<year>1984</year>) <article-title>Panic symptoms after inhalation of carbon dioxide</article-title>. <source>Br J Psychiatry</source> <volume>144</volume>: <fpage>503</fpage>–<lpage>507</lpage>.</citation>
</ref>
<ref id="bibr129-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Van Duinen</surname><given-names>MA</given-names></name>
<name><surname>Schruers</surname><given-names>KR</given-names></name>
<name><surname>Jaegers</surname><given-names>E</given-names></name>
<name><surname>Maes</surname><given-names>M</given-names></name>
<name><surname>Griez</surname><given-names>EJ</given-names></name>
</person-group> (<year>2004</year>) <article-title>Salivary cortisol in panic: are males more vulnerable?</article-title>. <source>Neuro Endocrinol Lett</source> <volume>25</volume>: <fpage>386</fpage>–<lpage>390</lpage>.</citation>
</ref>
<ref id="bibr130-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Van Duinen</surname><given-names>MA</given-names></name>
<name><surname>Schruers</surname><given-names>KR</given-names></name>
<name><surname>Maes</surname><given-names>M</given-names></name>
<name><surname>Griez</surname><given-names>EJ</given-names></name>
</person-group> (<year>2007</year>) <article-title>CO<sub>2</sub> challenge induced HPA axis activation in panic</article-title>. <source>Int J Neuropsychopharmacol</source> <volume>10</volume>: <fpage>797</fpage>–<lpage>804</lpage>.</citation>
</ref>
<ref id="bibr131-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vollebergh</surname><given-names>WAM</given-names></name>
<name><surname>Iedema</surname><given-names>J</given-names></name>
<name><surname>Bijl</surname><given-names>RV</given-names></name>
<name><surname>de Graaf</surname><given-names>R</given-names></name>
<name><surname>Smit</surname><given-names>F</given-names></name>
<name><surname>Ormel</surname><given-names>J</given-names></name>
</person-group> (<year>2001</year>) <article-title>The structure and stability of common mental disorders: The NEMESIS Study</article-title>. <source>Arch Gen Psychiatry</source> <volume>58</volume>: <fpage>597</fpage>–<lpage>603</lpage>.</citation>
</ref>
<ref id="bibr132-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Watson</surname><given-names>D</given-names></name>
</person-group> (<year>2005</year>) <article-title>Rethinking the mood and anxiety disorders: a quantitative hierarchical model for DSM-V</article-title>. <source>J Abnorm Psychol</source> <volume>114</volume>: <fpage>522</fpage>–<lpage>536</lpage>.</citation>
</ref>
<ref id="bibr133-0269881110372818">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wittchen</surname><given-names>HU</given-names></name>
<name><surname>Jacobi</surname><given-names>F</given-names></name>
</person-group> (<year>2005</year>) <article-title>Size and burden of mental disorders in Europe – a critical review and appraisal of 27 studies</article-title>. <source>Eur Neuropsychopharmacol</source> <volume>15</volume>: <fpage>357</fpage>–<lpage>376</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>